Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6088752,si,"Consequently the sieving coefficients of salicylic acid and antipyrine in one rat are not significantly different from one but in the other are significantly smaller than one, resulting in 0.6-0.7 in average.",Solvent drag in jejunal absorption of salicylic acid and antipyrine obtained by in situ single-pass perfusion method in rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6088752/),,0.6-0.7,1987,DB00936,Salicylic acid
,17312018,influx clearances,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),[ml] / [g·min],0.0407,4518,DB00936,Salicylic acid
,17312018,influx clearances,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),[ml] / [g·min],0.0813,4519,DB00936,Salicylic acid
,17312018,k2,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ","λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),1/[min],0.0238,4520,DB00936,Salicylic acid
,17312018,k3,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),1/[min],0.0238,4521,DB00936,Salicylic acid
,17312018,k3,"The developed model could adequately explain the concentration profiles of salicylic acid in the effluents with influx clearances from maternal and fetal perfusates to placental tissue of 0.0407 and 0.0813 ml/min/g cotyledon and efflux rate constants from placental tissue to maternal and fetal perfusates (k2 and k3) of 0.0238 and 0.176 min(-1), respectively.","Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),1/[min],0.176,4522,DB00936,Salicylic acid
,17312018,K''1/k2,The K''1/k2 value of salicylic acid was 1.07 ml/g cotyledon and was larger than that of antipyrine (0.642 ml/g cotyledon).,"Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),[ml] / [g],1.07,4523,DB00936,Salicylic acid
,17312018,K''1/k2,The K''1/k2 value of salicylic acid was 1.07 ml/g cotyledon and was larger than that of antipyrine (0.642 ml/g cotyledon).,"Kinetic analysis of the transport of salicylic acid, a nonsteroidal anti-inflammatory drug, across human placenta. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17312018/),[ml] / [g],0.642,4524,DB00936,Salicylic acid
,9044241,recovery,"The recovery of ASA, SA and SUA was between 90-105%.","A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044241/),%,90-105,5501,DB00936,Salicylic acid
,23081668,total run time,The total run time was 3.00 min; the developed method was validated in human plasma with a lower limit of quantitation of 0.99 ng/mL for aspirin and 2.01 ng/mL for salicylic acid.,Low dose aspirin estimation: an application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23081668/),min,3.00,5709,DB00936,Salicylic acid
,23081668,total run time,The total run time was 3.00 min; the developed method was validated in human plasma with a lower limit of quantitation of 0.99 ng/mL for aspirin and 2.01 ng/mL for salicylic acid.,Low dose aspirin estimation: an application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23081668/),ng,2.01,5710,DB00936,Salicylic acid
,1261159,T1/2,"Tolmetin, a nonsteroidal anti-inflammatory drug, is rapidly absorbed (10 to 20 min) and rapidly excreted (T1/2 congruent to 60 min) and shows a linear dose-plasma level response in the therapeutic dose range.",Absorption and excretion of tolemetin in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261159/),min,60,6105,DB00936,Salicylic acid
,3705620,excretion,"The excretion of salicylic acid was found to be highly variable within the study panel (1.3-31% of dose in 12 h), and was related to both urine volume and pH.",The metabolism of aspirin in man: a population study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705620/),%,1.3-31,6997,DB00936,Salicylic acid
,3705620,excretion,"The excretion of the two salicyl glucuronides was highly variable, ranging from 0.8 to 42% of the dose.",The metabolism of aspirin in man: a population study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3705620/),%,0.8 to 42,6998,DB00936,Salicylic acid
,31870960,solubility,"In vitro study indicates that the solubility of ChBP-GA and ChBP-SA cocrystals increase to 3724.4 ± 58.7, 2897.4 ± 81.9 μg/mL in comparison with ChBP (2561.3 ± 150.4 μg/mL), the intrinsic dissolution rates (IDRs) of ChBP-GA and ChBP-SA cocrystals (721.3 ± 8.0, 614.4 ± 13.2 μg/min/cm2) are both higher than ChBP (537.9 ± 12.0 μg/min/cm2).","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[μg] / [ml],3724.4,11268,DB00936,Salicylic acid
,31870960,solubility,"In vitro study indicates that the solubility of ChBP-GA and ChBP-SA cocrystals increase to 3724.4 ± 58.7, 2897.4 ± 81.9 μg/mL in comparison with ChBP (2561.3 ± 150.4 μg/mL), the intrinsic dissolution rates (IDRs) of ChBP-GA and ChBP-SA cocrystals (721.3 ± 8.0, 614.4 ± 13.2 μg/min/cm2) are both higher than ChBP (537.9 ± 12.0 μg/min/cm2).","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[μg] / [ml],2897.4,11269,DB00936,Salicylic acid
,31870960,solubility,"In vitro study indicates that the solubility of ChBP-GA and ChBP-SA cocrystals increase to 3724.4 ± 58.7, 2897.4 ± 81.9 μg/mL in comparison with ChBP (2561.3 ± 150.4 μg/mL), the intrinsic dissolution rates (IDRs) of ChBP-GA and ChBP-SA cocrystals (721.3 ± 8.0, 614.4 ± 13.2 μg/min/cm2) are both higher than ChBP (537.9 ± 12.0 μg/min/cm2).","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[μg] / [ml],2561.3,11270,DB00936,Salicylic acid
,31870960,intrinsic dissolution rates (IDRs),"In vitro study indicates that the solubility of ChBP-GA and ChBP-SA cocrystals increase to 3724.4 ± 58.7, 2897.4 ± 81.9 μg/mL in comparison with ChBP (2561.3 ± 150.4 μg/mL), the intrinsic dissolution rates (IDRs) of ChBP-GA and ChBP-SA cocrystals (721.3 ± 8.0, 614.4 ± 13.2 μg/min/cm2) are both higher than ChBP (537.9 ± 12.0 μg/min/cm2).","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[μg] / [cm2·min],721.3,11271,DB00936,Salicylic acid
,31870960,intrinsic dissolution rates (IDRs),"In vitro study indicates that the solubility of ChBP-GA and ChBP-SA cocrystals increase to 3724.4 ± 58.7, 2897.4 ± 81.9 μg/mL in comparison with ChBP (2561.3 ± 150.4 μg/mL), the intrinsic dissolution rates (IDRs) of ChBP-GA and ChBP-SA cocrystals (721.3 ± 8.0, 614.4 ± 13.2 μg/min/cm2) are both higher than ChBP (537.9 ± 12.0 μg/min/cm2).","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[μg] / [cm2·min],614.4,11272,DB00936,Salicylic acid
,31870960,intrinsic dissolution rates (IDRs),"In vitro study indicates that the solubility of ChBP-GA and ChBP-SA cocrystals increase to 3724.4 ± 58.7, 2897.4 ± 81.9 μg/mL in comparison with ChBP (2561.3 ± 150.4 μg/mL), the intrinsic dissolution rates (IDRs) of ChBP-GA and ChBP-SA cocrystals (721.3 ± 8.0, 614.4 ± 13.2 μg/min/cm2) are both higher than ChBP (537.9 ± 12.0 μg/min/cm2).","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[μg] / [cm2·min],537.9,11273,DB00936,Salicylic acid
,31870960,blood concentration peak values,"The blood concentration peak values of ChBP-GA and ChBP-SA cocrystals (165.8 ± 50.9, 105.3 ± 35.6 ng/mL) are both higher than ChBP (51.3 ± 15.1 ng/mL) in in vivo evaluation.","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[ng] / [ml],165.8,11274,DB00936,Salicylic acid
,31870960,blood concentration peak values,"The blood concentration peak values of ChBP-GA and ChBP-SA cocrystals (165.8 ± 50.9, 105.3 ± 35.6 ng/mL) are both higher than ChBP (51.3 ± 15.1 ng/mL) in in vivo evaluation.","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[ng] / [ml],105.3,11275,DB00936,Salicylic acid
,31870960,blood concentration peak values,"The blood concentration peak values of ChBP-GA and ChBP-SA cocrystals (165.8 ± 50.9, 105.3 ± 35.6 ng/mL) are both higher than ChBP (51.3 ± 15.1 ng/mL) in in vivo evaluation.","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),[ng] / [ml],51.3,11276,DB00936,Salicylic acid
,31870960,elimination,"ChBP-FA cocrystal presents a longer elimination half life (t1/2 = 10.0 ± 2.6 h), which makes it a potential candidate for prolonged controlled release formulation.","Crystal structures, dissolution and pharmacokinetic study on a novel phosphodiesterase-4 inhibitor chlorbipram cocrystals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31870960/),h,10.0,11277,DB00936,Salicylic acid
,28526350,plasma half-life,"After oral administration in rabbit models, conjugates 2 and 6 showed plasma half-life of 6.96 and 7.01h with maximum plasma concentration (Cmax) of 15.27 and 23.01μg L-1, respectively, and each reached peak plasma concentration (tmax) at 4.0h.",Designing novel bioconjugates of hydroxyethyl cellulose and salicylates for potential pharmaceutical and pharmacological applications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526350/),h,6.96,11725,DB00936,Salicylic acid
,28526350,plasma half-life,"After oral administration in rabbit models, conjugates 2 and 6 showed plasma half-life of 6.96 and 7.01h with maximum plasma concentration (Cmax) of 15.27 and 23.01μg L-1, respectively, and each reached peak plasma concentration (tmax) at 4.0h.",Designing novel bioconjugates of hydroxyethyl cellulose and salicylates for potential pharmaceutical and pharmacological applications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526350/),h,7.01,11726,DB00936,Salicylic acid
,28526350,maximum plasma concentration (Cmax),"After oral administration in rabbit models, conjugates 2 and 6 showed plasma half-life of 6.96 and 7.01h with maximum plasma concentration (Cmax) of 15.27 and 23.01μg L-1, respectively, and each reached peak plasma concentration (tmax) at 4.0h.",Designing novel bioconjugates of hydroxyethyl cellulose and salicylates for potential pharmaceutical and pharmacological applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526350/),[μg] / [l],15.27,11727,DB00936,Salicylic acid
,28526350,maximum plasma concentration (Cmax),"After oral administration in rabbit models, conjugates 2 and 6 showed plasma half-life of 6.96 and 7.01h with maximum plasma concentration (Cmax) of 15.27 and 23.01μg L-1, respectively, and each reached peak plasma concentration (tmax) at 4.0h.",Designing novel bioconjugates of hydroxyethyl cellulose and salicylates for potential pharmaceutical and pharmacological applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28526350/),[μg] / [l],23.01,11728,DB00936,Salicylic acid
,3557190,distribution half-life,After an intravenous injection of 3.26 mmol 5ASA serum concentrations fell rapidly with a distribution half-life of 17 +/- 2 min and an elimination half-life of 42 +/- 5 min.,Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),min,17,12912,DB00936,Salicylic acid
,3557190,elimination half-life,After an intravenous injection of 3.26 mmol 5ASA serum concentrations fell rapidly with a distribution half-life of 17 +/- 2 min and an elimination half-life of 42 +/- 5 min.,Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),min,42,12913,DB00936,Salicylic acid
,3557190,Bioavailabilities,"Bioavailabilities which ranged from 19% for ileocaecal release to 75% for release in the upper gastrointestinal tract, were calculated from areas under the serum concentration curves.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,19,12914,DB00936,Salicylic acid
,3557190,Bioavailabilities,"Bioavailabilities which ranged from 19% for ileocaecal release to 75% for release in the upper gastrointestinal tract, were calculated from areas under the serum concentration curves.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,75,12915,DB00936,Salicylic acid
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,78,12916,DB00936,Salicylic acid
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,52,12917,DB00936,Salicylic acid
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,55,12918,DB00936,Salicylic acid
,3557190,Urinary excretion,"Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.",Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557190/),%,21,12919,DB00936,Salicylic acid
,25571846,peak plasma concentration,"Mean peak plasma concentration values for groups treated with 200, 400 and 800 mg/kg doses ranged from 48.79 to 171.83 μg/mL after single-dose oral administration of MSL, and mean area under the concentration-time curve values ranged from 195.16 to 1107.76 μg/mL h.",Lack of dose dependent kinetics of methyl salicylate-2-O-β-D-lactoside in rhesus monkeys after oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25571846/),[μg] / [ml],48.79 to 171.83,13633,DB00936,Salicylic acid
,25571846,area under the concentration-time curve,"Mean peak plasma concentration values for groups treated with 200, 400 and 800 mg/kg doses ranged from 48.79 to 171.83 μg/mL after single-dose oral administration of MSL, and mean area under the concentration-time curve values ranged from 195.16 to 1107.76 μg/mL h.",Lack of dose dependent kinetics of methyl salicylate-2-O-β-D-lactoside in rhesus monkeys after oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25571846/),[μg] / [h·ml],195.16 to 1107.76,13634,DB00936,Salicylic acid
,25571846,Absolute bioavailability,"Absolute bioavailability of MSL was assessed to be 118.89 ± 57.50, 213.54 ± 58.98 and 168.72 ± 76.58%, respectively.",Lack of dose dependent kinetics of methyl salicylate-2-O-β-D-lactoside in rhesus monkeys after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25571846/),%,118.89,13635,DB00936,Salicylic acid
,25571846,Absolute bioavailability,"Absolute bioavailability of MSL was assessed to be 118.89 ± 57.50, 213.54 ± 58.98 and 168.72 ± 76.58%, respectively.",Lack of dose dependent kinetics of methyl salicylate-2-O-β-D-lactoside in rhesus monkeys after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25571846/),%,213.54,13636,DB00936,Salicylic acid
,25571846,Absolute bioavailability,"Absolute bioavailability of MSL was assessed to be 118.89 ± 57.50, 213.54 ± 58.98 and 168.72 ± 76.58%, respectively.",Lack of dose dependent kinetics of methyl salicylate-2-O-β-D-lactoside in rhesus monkeys after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25571846/),%,168.72,13637,DB00936,Salicylic acid
excess,25571846,apparent absolute bioavailability,"Pharmacokinetics parameters did not appear to be dose proportional among the three oral doses of treatments, and MSL showed an apparent absolute bioavailability in excess of 100% in rhesus monkeys based on the present study.",Lack of dose dependent kinetics of methyl salicylate-2-O-β-D-lactoside in rhesus monkeys after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25571846/),%,100,13638,DB00936,Salicylic acid
,10494706,Cmax (maximum concentration),"The mean Cmax (maximum concentration) of total, unbound salicylic acid was 9.5 microg/ml in microdialysates, 13.2 microg/ml in suction blister fluid and 56.5 microg/ml in plasma.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),[μg] / [ml],9.5,19458,DB00936,Salicylic acid
,10494706,Cmax (maximum concentration),"The mean Cmax (maximum concentration) of total, unbound salicylic acid was 9.5 microg/ml in microdialysates, 13.2 microg/ml in suction blister fluid and 56.5 microg/ml in plasma.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),[μg] / [ml],13.2,19459,DB00936,Salicylic acid
,10494706,Cmax (maximum concentration),"The mean Cmax (maximum concentration) of total, unbound salicylic acid was 9.5 microg/ml in microdialysates, 13.2 microg/ml in suction blister fluid and 56.5 microg/ml in plasma.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),[μg] / [ml],56.5,19460,DB00936,Salicylic acid
,10494706,Tmax (time to Cmax),"Mean Tmax (time to Cmax) for salicylic acid was 188 and 161 min in plasma and microdialysates, respectively.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),min,188,19461,DB00936,Salicylic acid
,10494706,Tmax (time to Cmax),"Mean Tmax (time to Cmax) for salicylic acid was 188 and 161 min in plasma and microdialysates, respectively.",Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),min,161,19462,DB00936,Salicylic acid
,10494706,dermis-to-plasma Cmax ratio,The dermis-to-plasma Cmax ratio was 0.16+/-0.04 (mean +/- SD) by microdialysis sampling and 0.25+/-0.09 by the suction blister fluid method.,Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),,0.16,19463,DB00936,Salicylic acid
,10494706,dermis-to-plasma Cmax ratio,The dermis-to-plasma Cmax ratio was 0.16+/-0.04 (mean +/- SD) by microdialysis sampling and 0.25+/-0.09 by the suction blister fluid method.,Microdialysis vs. suction blister technique for in vivo sampling of pharmacokinetics in the human dermis. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494706/),,0.25,19464,DB00936,Salicylic acid
,1809699,relative bioavailability,"The results showed no difference between the area under concentration time curve (AUC0-infinity) ASA values of both formulations (p = 0.19), and buffered ASA relative bioavailability was 102.49% (= bioequivalence).",Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809699/),%,102.49,20342,DB00936,Salicylic acid
,1809699,AUC0-30 min,A significant difference was found between the AUC0-30 min ASA values: 90.5 micrograms.,Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809699/),μg,90.5,20343,DB00936,Salicylic acid
,1809699,time of maximum concentration,"The buffered ASA time of maximum concentration was shorter (28 +/- 8 min) than the plain one (38 +/- 19 min, p less than 0.05).",Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809699/),min,28,20344,DB00936,Salicylic acid
,1809699,time of maximum concentration,"The buffered ASA time of maximum concentration was shorter (28 +/- 8 min) than the plain one (38 +/- 19 min, p less than 0.05).",Pharmacokinetic study of a new oral buffered acetylsalicylic acid (ASA) formulation in comparison with plain ASA in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1809699/),min,38,20345,DB00936,Salicylic acid
,2092574,T1/2ka,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),h,1.25,21536,DB00936,Salicylic acid
,2092574,T1/2ke,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),h,3.28,21537,DB00936,Salicylic acid
,2092574,ka,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),1/[h],0.5554,21538,DB00936,Salicylic acid
,2092574,ke,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),1/[h],0.2111,21539,DB00936,Salicylic acid
,2092574,Tmax,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),h,3.02,21540,DB00936,Salicylic acid
,2092574,Cmax,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),[μg] / [ml],331.46,21541,DB00936,Salicylic acid
,2092574,AUC,"The plasma SLA concentration-time curve obtained after oral administration of GASL to rats was shown to fit a one compartment open model with the following pharmacokinetic parameters: T1/2ka = 1.25 h, T1/2ke = 3.28 h, ka = 0.5554/h, ke = 0.2111/h, Tmax = 3.02 h, Cmax = 331.46 micrograms/ml, AUC = 2832.93 micrograms/ml.h",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),[μg] / [h·ml],2832.93,21542,DB00936,Salicylic acid
,2092574,total,"Within 24 h following ig administration of GASL the total SLA excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),,10.9,21543,DB00936,Salicylic acid
,2092574,total,"Within 24 h following ig administration of GASL the total SLA excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),,0.41,21544,DB00936,Salicylic acid
,2092574,excreted,"Within 24 h following ig administration of GASL the total SLA excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),,10.9,21545,DB00936,Salicylic acid
,2092574,excreted,"Within 24 h following ig administration of GASL the total SLA excreted in urine and feces was 10.9 and 0.41 of the GASL dose, respectively.",[The physiologic disposition and pharmacokinetics of guaiacol acetylsalicylate in rats]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092574/),,0.41,21546,DB00936,Salicylic acid
,7833225,target concentrations,"An aqueous solution (0.1 to 0.2 ml) containing paracetamol, salicylate, diclofenac and [125I]-albumin was injected into a given joint to yield target concentrations of approximately 20 micrograms ml-1 for diclofenac, salicylate and paracetamol and 10(8) counts ml-1 for [125I]-albumin.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[μg] / [ml],20,23157,DB00936,Salicylic acid
,7833225,target concentrations,"An aqueous solution (0.1 to 0.2 ml) containing paracetamol, salicylate, diclofenac and [125I]-albumin was injected into a given joint to yield target concentrations of approximately 20 micrograms ml-1 for diclofenac, salicylate and paracetamol and 10(8) counts ml-1 for [125I]-albumin.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[counts] / [ml],10,23158,DB00936,Salicylic acid
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.0053,23159,DB00936,Salicylic acid
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.0096,23160,DB00936,Salicylic acid
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.024,23161,DB00936,Salicylic acid
,7833225,clearances,"3. The clearances (+/- s.d.) obtained for the solutes were [125I]-albumin (0.0053 +/- 0.0019 l h-1), diclofenac (0.0096 +/- 0.0061 l h-1), salicylate (0.024 +/- 0.022 l h-1) and paracetamol (0.055 +/- 0.041 l h-1).",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),[l] / [h],0.055,23162,DB00936,Salicylic acid
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.0,23163,DB00936,Salicylic acid
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,<,23164,DB00936,Salicylic acid
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.01,23165,DB00936,Salicylic acid
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.34,23166,DB00936,Salicylic acid
,7833225,fractions unbound,"The corresponding fractions unbound of these solutes in synovial fluid were 0.0, < or = 0.01, 0.34 +/- 0.09 and 0.85 +/- 0.10, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.85,23167,DB00936,Salicylic acid
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0,23168,DB00936,Salicylic acid
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.87,23169,DB00936,Salicylic acid
,7833225,Diffusion,"4. Diffusion of unbound solute through the synovium is estimated to account for (+/- s.d.) 0.52 +/- 0.08, 0.87 +/- 0.06 and 0.99 +/- 0.01 of the total clearance of diclofenac, salicylate and paracetamol from the joint space, respectively.",Disappearance kinetics of solutes from synovial fluid after intra-articular injection. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833225/),,0.99,23170,DB00936,Salicylic acid
,7309902,time to peak level,"Following a single dose, SSA was promptly absorbed (mean time to peak level 1.5 hour) and was eliminated from plasma with a mean half-life of 1.1 hour.","Absorption, biotransformation, and pharmacokinetics of salicylsalicylic acid in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309902/),h,1.5,30073,DB00936,Salicylic acid
,7309902,half-life,"Following a single dose, SSA was promptly absorbed (mean time to peak level 1.5 hour) and was eliminated from plasma with a mean half-life of 1.1 hour.","Absorption, biotransformation, and pharmacokinetics of salicylsalicylic acid in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7309902/),h,1.1,30074,DB00936,Salicylic acid
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB00936,Salicylic acid
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB00936,Salicylic acid
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB00936,Salicylic acid
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB00936,Salicylic acid
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB00936,Salicylic acid
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB00936,Salicylic acid
,22057729,time to maximum plasma concentrations (T(max)),Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged.,Dissolution and pharmacokinetics of a novel micronized aspirin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057729/),min,17.5,32048,DB00936,Salicylic acid
,22057729,time to maximum plasma concentrations (T(max)),Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged.,Dissolution and pharmacokinetics of a novel micronized aspirin formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057729/),min,45,32049,DB00936,Salicylic acid
,22057729,maximum plasma concentration (C(max)),Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged.,Dissolution and pharmacokinetics of a novel micronized aspirin formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057729/),[μg] / [ml],13.8,32050,DB00936,Salicylic acid
,22057729,maximum plasma concentration (C(max)),Plasma concentration time curve comparison to regular 500 mg aspirin tablets showed a substantial improvement in the time to maximum plasma concentrations (T(max)) (ASA 17.5 min vs. 45 min) and an increase in maximum plasma concentration (C(max)) (ASA 13.8 μg/ml vs. 4.4 μg/ml) while the overall extent of exposure (AUC) remains almost unchanged.,Dissolution and pharmacokinetics of a novel micronized aspirin formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22057729/),[μg] / [ml],4.4,32051,DB00936,Salicylic acid
,1981545,steady-state plasma concentration,Indomethacin was administered as iv bolus injection and iv infusion to yield a steady-state plasma concentration of approximately 1 microgram/ml.,Effects of sodium salicylate on elimination kinetics of indomethacin and bile production in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1981545/),[μg] / [ml],1,32541,DB00936,Salicylic acid
,8980919,Cmax,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [ml],10.04,33133,DB00936,Salicylic acid
,8980919,AUC0-6h,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [h·ml],14.03,33134,DB00936,Salicylic acid
,8980919,AUC0-6h,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [h·ml],86.51,33135,DB00936,Salicylic acid
,8980919,AUC0-6h,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,1.04,33136,DB00936,Salicylic acid
,8980919,t1/2,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,1.04,33137,DB00936,Salicylic acid
,8980919,t1/2,"The Cmax, AUC0-6h and t1/2 for aspirin increased from 10.04 +/- 0.1 mg/ml to 28.62 +/- 0.21 mg/ml (P < 0.05); 14.03 +/- 0.11 mg/ml.h to 86.51 +/- 0.21 mg/ml.h (P < 0.085) and 1.04 +/- 0.12 h to 1.50 +/- 0.44 h (P < 0.05) respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,1.50,33138,DB00936,Salicylic acid
,8980919,tmax,There was no change in the tmax (0.50 +/- 0.17 h) but there was a decrease in the kel from 0.633 +/- 0.22 to 0.463 +/- 0.29 (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,0.50,33139,DB00936,Salicylic acid
,8980919,kel,There was no change in the tmax (0.50 +/- 0.17 h) but there was a decrease in the kel from 0.633 +/- 0.22 to 0.463 +/- 0.29 (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,0.633,33140,DB00936,Salicylic acid
,8980919,kel,There was no change in the tmax (0.50 +/- 0.17 h) but there was a decrease in the kel from 0.633 +/- 0.22 to 0.463 +/- 0.29 (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,0.463,33141,DB00936,Salicylic acid
,8980919,Cmax,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [ml],43.84,33142,DB00936,Salicylic acid
,8980919,AUC0-6h,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [ml],68.19,33143,DB00936,Salicylic acid
,8980919,AUC0-6h,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [h·ml],171.59,33144,DB00936,Salicylic acid
,8980919,AUC0-6h,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),[mg] / [·h·ml],266.22,33145,DB00936,Salicylic acid
,8980919,AUC0-6h,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,7.37,33146,DB00936,Salicylic acid
,8980919,kel,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,7.37,33147,DB00936,Salicylic acid
,8980919,kel,"Similarly, the Cmax, AUC0-6h and kel for salicylic acid rose from 43.84 +/- 0.21 mg/ml to 68.19 +/- 0.71 mg/ml (P < 0.05); 171.59 +/- 0.07 mg/ml.h to 266.22 +/- 0.21 mg/ml/.h (P < 0.05) and 7.37 +/- 0.29 to 19.30 +/- 0.21 (P < 0.05), respectively.",Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),,19.30,33148,DB00936,Salicylic acid
,8980919,tmax,The tmax decreased from 2.0 +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 +/- 0.11 h (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,2.0,33149,DB00936,Salicylic acid
,8980919,tmax,The tmax decreased from 2.0 +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 +/- 0.11 h (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,1.0,33150,DB00936,Salicylic acid
,8980919,t1/2,The tmax decreased from 2.0 +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 +/- 0.11 h (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,0.25,33151,DB00936,Salicylic acid
,8980919,t1/2,The tmax decreased from 2.0 +/- 0.18 h to 1.0 +/- 0.08 h (P < 0.05) and t1/2 from 0.25 +/- 0.21 h to 0.184 +/- 0.11 h (P < 0.05).,Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8980919/),h,0.184,33152,DB00936,Salicylic acid
,25869458,kD,"The validated model was used to simulate bioequivalence trials at 3 dose schemes (100, 1000 and 3000 mg) and with 6 test formulations with decreasing in vivo dissolution rate constants versus the reference formulation (kD 8-0.25 h (-1)).",Semi-physiologic model validation and bioequivalence trials simulation to select the best analyte for acetylsalicylic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869458/),-1·h,8-0.25,36588,DB00936,Salicylic acid
,6873151,systemic availability,"The systemic availability of acetylsalicylic acid (ASA) after oral ingestion of 1 g in an effervescent formulation was 16.3 +/- 2.0% and 16.9 +/- 3.2% of the ingested dose in normal women and men, respectively.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),%,16.3,40819,DB00936,Salicylic acid
,6873151,systemic availability,"The systemic availability of acetylsalicylic acid (ASA) after oral ingestion of 1 g in an effervescent formulation was 16.3 +/- 2.0% and 16.9 +/- 3.2% of the ingested dose in normal women and men, respectively.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),%,16.9,40820,DB00936,Salicylic acid
,6873151,plasma half-life,"The average plasma half-life of ASA in each sex was also identical at 18.5 +/- 1.4 and 18.1 +/- 1.2 min, respectively.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),min,18.5,40821,DB00936,Salicylic acid
,6873151,plasma half-life,"The average plasma half-life of ASA in each sex was also identical at 18.5 +/- 1.4 and 18.1 +/- 1.2 min, respectively.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),min,18.1,40822,DB00936,Salicylic acid
,6873151,IC50,"The IC50 was 23.9 +/- 2.9 micrograms/ml in females and 22.5 +/- 2.7 micrograms/ml in males, which did not differ significantly.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),[μg] / [ml],23.9,40823,DB00936,Salicylic acid
,6873151,IC50,"The IC50 was 23.9 +/- 2.9 micrograms/ml in females and 22.5 +/- 2.7 micrograms/ml in males, which did not differ significantly.",Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),[μg] / [ml],22.5,40824,DB00936,Salicylic acid
,6873151,IC50,The inhibition by salicylic acid (SA) of the antiaggregatory effect of ASA was similar in both sexes with increases in IC50 to 33.5 +/- 5.1 micrograms/ml in females (p less than 0.02) and to 29.5 +/- 3.8 micrograms/ml in males (p less than 0.05).,Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),[μg] / [ml],33.5,40825,DB00936,Salicylic acid
,6873151,IC50,The inhibition by salicylic acid (SA) of the antiaggregatory effect of ASA was similar in both sexes with increases in IC50 to 33.5 +/- 5.1 micrograms/ml in females (p less than 0.02) and to 29.5 +/- 3.8 micrograms/ml in males (p less than 0.05).,Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6873151/),[μg] / [ml],29.5,40826,DB00936,Salicylic acid
,28664587,body clearance,"As the age increased from 6 to 13 weeks (body weight increase from 2.35 to 9.43 kg), median body clearance decreased from 1.34 to 0.87 ml/min/kg.",The influence of rapid growth on sodium salicylate pharmacokinetics in male turkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28664587/),[ml] / [kg·min],1,43380,DB00936,Salicylic acid
,28664587,body clearance,"As the age increased from 6 to 13 weeks (body weight increase from 2.35 to 9.43 kg), median body clearance decreased from 1.34 to 0.87 ml/min/kg.",The influence of rapid growth on sodium salicylate pharmacokinetics in male turkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28664587/),[ml] / [kg·min],0,43381,DB00936,Salicylic acid
,28664587,mean residence time,This caused a significant increase in the median mean residence time from 3.42 to 4.44 hr.,The influence of rapid growth on sodium salicylate pharmacokinetics in male turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28664587/),h,3.42,43382,DB00936,Salicylic acid
,28664587,mean residence time,This caused a significant increase in the median mean residence time from 3.42 to 4.44 hr.,The influence of rapid growth on sodium salicylate pharmacokinetics in male turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28664587/),h,4.44,43383,DB00936,Salicylic acid
,3735085,absolute bioavailability,"The estimated absolute bioavailability was 0.432 +/- 0.0213 and 0.527 +/- 0.0260 for enteric coated and plain aspirin, respectively.",Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),,0.432,45524,DB00936,Salicylic acid
,3735085,absolute bioavailability,"The estimated absolute bioavailability was 0.432 +/- 0.0213 and 0.527 +/- 0.0260 for enteric coated and plain aspirin, respectively.",Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),,0.527,45525,DB00936,Salicylic acid
,3735085,highest observed plasma concentration (Cmax),Other pharmacokinetic parameters for these two dosage forms such as the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 1.94 min versus 31.0 +/- 7.04 min) agree well.,Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),[μg] / [ml],10.9,45526,DB00936,Salicylic acid
,3735085,highest observed plasma concentration (Cmax),Other pharmacokinetic parameters for these two dosage forms such as the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 1.94 min versus 31.0 +/- 7.04 min) agree well.,Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),[μg] / [ml],13.6,45527,DB00936,Salicylic acid
,3735085,time to reach Cmax (tmax),Other pharmacokinetic parameters for these two dosage forms such as the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 1.94 min versus 31.0 +/- 7.04 min) agree well.,Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),min,26.6,45528,DB00936,Salicylic acid
,3735085,time to reach Cmax (tmax),Other pharmacokinetic parameters for these two dosage forms such as the highest observed plasma concentration (Cmax) (10.9 +/- 0.535 microgram/mL versus 13.6 +/- 1.88 micrograms/mL) and the time to reach Cmax (tmax) (26.6 +/- 1.94 min versus 31.0 +/- 7.04 min) agree well.,Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),min,31.0,45529,DB00936,Salicylic acid
,3735085,gastric emptying time,"The mean values for gastric emptying time, in vivo coating dissolution time, and in vivo disintegration/dissolution time of the tablet core for enteric coated aspirin are 48.7 +/- 7.23 min, 44.3 +/- 3.80 min, and 34.7 +/- 2.04 min, respectively.",Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),min,48.7,45530,DB00936,Salicylic acid
,3735085,disintegration/dissolution time,"The mean values for gastric emptying time, in vivo coating dissolution time, and in vivo disintegration/dissolution time of the tablet core for enteric coated aspirin are 48.7 +/- 7.23 min, 44.3 +/- 3.80 min, and 34.7 +/- 2.04 min, respectively.",Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735085/),min,34.7,45531,DB00936,Salicylic acid
,2104082,peak median plasma bismuth concentration,The peak median plasma bismuth concentration was at +240 min (1.7 ng/ml; range 0.8-5.3 ng/ml).,The absorption of bismuth and salicylate from oral doses of Pepto-Bismol (bismuth salicylate). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2104082/),[ng] / [ml],1.7,46674,DB00936,Salicylic acid
,21755814,m/z,"The multiple reaction monitoring (MRM) transitions m/z 179 --> 137 for ASA, m/z 137 --> 65 for SA and m/z 294 --> 250 for IS were used.",Simultaneous extraction of acetylsalicylic acid and salicylic acid from human plasma and simultaneous estimation by liquid chromatography and atmospheric pressure chemical ionization/tandem mass spectrometry detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755814/),,137,47440,DB00936,Salicylic acid
,21755814,m/z,"The multiple reaction monitoring (MRM) transitions m/z 179 --> 137 for ASA, m/z 137 --> 65 for SA and m/z 294 --> 250 for IS were used.",Simultaneous extraction of acetylsalicylic acid and salicylic acid from human plasma and simultaneous estimation by liquid chromatography and atmospheric pressure chemical ionization/tandem mass spectrometry detection. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21755814/),,65,47441,DB00936,Salicylic acid
,2490276,bioavailability,"However, GM absorption was marked when 90 mg of solid SA or CA was added (the bioavailability of GM was 58% with SA, and 59% with CA).",Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490276/),%,58,47771,DB00936,Salicylic acid
,2490276,bioavailability,"However, GM absorption was marked when 90 mg of solid SA or CA was added (the bioavailability of GM was 58% with SA, and 59% with CA).",Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490276/),%,59,47772,DB00936,Salicylic acid
,2490276,Cmax,"In the case of SA, the highest plasma GM level (Cmax 15.3 +/- 1.7 micrograms/ml, AUC0-4 27.3 +/- 3.9 h.micrograms/ml) was obtained following coadministration of powdered GM and SA; the plasma GM level (Cmax 1.5 +/- 0.6 micrograms/ml, AUC0-4 3.0 +/- 1.3 h.micrograms/ml) following the administration of a solution of GM and SA was significantly decreased as compared with the results using the powdered form.",Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490276/),[μg] / [ml],15.3,47773,DB00936,Salicylic acid
,2490276,AUC0-4,"In the case of SA, the highest plasma GM level (Cmax 15.3 +/- 1.7 micrograms/ml, AUC0-4 27.3 +/- 3.9 h.micrograms/ml) was obtained following coadministration of powdered GM and SA; the plasma GM level (Cmax 1.5 +/- 0.6 micrograms/ml, AUC0-4 3.0 +/- 1.3 h.micrograms/ml) following the administration of a solution of GM and SA was significantly decreased as compared with the results using the powdered form.",Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490276/),[h·μg] / [ml],27.3,47774,DB00936,Salicylic acid
,2490276,Cmax,"In the case of SA, the highest plasma GM level (Cmax 15.3 +/- 1.7 micrograms/ml, AUC0-4 27.3 +/- 3.9 h.micrograms/ml) was obtained following coadministration of powdered GM and SA; the plasma GM level (Cmax 1.5 +/- 0.6 micrograms/ml, AUC0-4 3.0 +/- 1.3 h.micrograms/ml) following the administration of a solution of GM and SA was significantly decreased as compared with the results using the powdered form.",Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490276/),[μg] / [ml],1.5,47775,DB00936,Salicylic acid
,2490276,AUC0-4,"In the case of SA, the highest plasma GM level (Cmax 15.3 +/- 1.7 micrograms/ml, AUC0-4 27.3 +/- 3.9 h.micrograms/ml) was obtained following coadministration of powdered GM and SA; the plasma GM level (Cmax 1.5 +/- 0.6 micrograms/ml, AUC0-4 3.0 +/- 1.3 h.micrograms/ml) following the administration of a solution of GM and SA was significantly decreased as compared with the results using the powdered form.",Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490276/),[h·μg] / [ml],3.0,47776,DB00936,Salicylic acid
,2490276,Cmax,"In the case of CA, the plasma GM level (Cmax 14.8 +/- 4.5 micrograms/ml, AUC0-4 25.4 +/- 8.7 h.micrograms/ml) following administration of the solution form was not significantly decreased in comparison with the results obtained using the powdered form.",Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490276/),[μg] / [ml],14.8,47777,DB00936,Salicylic acid
,2490276,AUC0-4,"In the case of CA, the plasma GM level (Cmax 14.8 +/- 4.5 micrograms/ml, AUC0-4 25.4 +/- 8.7 h.micrograms/ml) following administration of the solution form was not significantly decreased in comparison with the results obtained using the powdered form.",Rectal absorption enhancement of gentamicin in rabbits from hollow type suppositories by sodium salicylate or sodium caprylate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2490276/),[h·μg] / [ml],25.4,47778,DB00936,Salicylic acid
,2406853,concentration of,"Extended dosing of Pepto-Bismol (3.14 g of BSS/d) for up to 6 weeks produced a mean concentration of bismuth in blood of 16.1 +/- 7.9 ng/g, considerably below concentrations in blood that have been reported to cause neurotoxicity.","Bismuth subsalicylate: history, chemistry, and safety. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2406853/),ng,16.1,48946,DB00936,Salicylic acid
,6858201,half-life,"(mainly salicylic acid) of 114, 194 and 320 micrograms equiv./ml respectively were reached at 4 h and then declined with a half-life of 6-7 h.","The metabolism of salicylidene benzylamine, a pro-drug for salicylate, in rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6858201/),h,6-7,51144,DB00936,Salicylic acid
,9876590,AUC0-5 hr,"The AUC0-5 hr was 73.7 +/- 43.5 mg.hr/dl compared to 242 +/- 70.5 mg.hr/dl for insulin (20 U, s.c.) with a relative hypoglycemia of 30.4%.",Hypoglycemic effect of oral insulin in diabetic rabbits using pH-dependent coated capsules containing sodium salicylate without and with sodium cholate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876590/),[h·mg] / [dl],73.7,56254,DB00936,Salicylic acid
,9876590,AUC0-5 hr,"The AUC0-5 hr was 73.7 +/- 43.5 mg.hr/dl compared to 242 +/- 70.5 mg.hr/dl for insulin (20 U, s.c.) with a relative hypoglycemia of 30.4%.",Hypoglycemic effect of oral insulin in diabetic rabbits using pH-dependent coated capsules containing sodium salicylate without and with sodium cholate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876590/),[h·mg] / [dl],242,56255,DB00936,Salicylic acid
,9876590,AUC0-5 hr,A higher dose of oral insulin (40 U) + sodium salicylate (50 mg) was more effective in reducing plasma glucose level which steadily decreased and reached 56% of the initial value by 5 hr (AUC0-5 hr = 132 +/- 41.5 mg.hr/dl and relative hypoglycemia = 27.3%).,Hypoglycemic effect of oral insulin in diabetic rabbits using pH-dependent coated capsules containing sodium salicylate without and with sodium cholate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876590/),[h·mg] / [dl],132,56256,DB00936,Salicylic acid
,9876590,AUC0-5 hr,"Sodium cholate (50 mg), however, slightly improved sodium salicylate effect producing an AUC0-5 hr of 139 +/- 37.3 mg.hr/dl with relative hypoglycemia of 28.7%.",Hypoglycemic effect of oral insulin in diabetic rabbits using pH-dependent coated capsules containing sodium salicylate without and with sodium cholate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9876590/),[h·mg] / [dl],139,56257,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,517.1,56914,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,174.9,56915,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,547.0,56916,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,204.9,56917,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,753.2,56918,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,205.2,56919,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,681.3,56920,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,443.3,56921,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,667.2,56922,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,205.1,56923,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,767.4,56924,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,529.2,56925,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,236.8,56926,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,103.2,56927,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,136.9/,56928,DB00936,Salicylic acid
,30340065,m/z,"The transitions of m/z were 517.1/174.9, 547.0/204.9, 753.2/205.2, 681.3/443.3, 667.2/205.1, 767.4/529.2, 236.8/103.2, and 136.9/92.9 for A5, A6, DSS, TFSA, TFSB, TFSC, TMCA, and salicylic acid (IS), respectively.",UHPLC-MS/MS method for simultaneous determination of Radix Polygalae glycolipids and organic acids in rat plasma and application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30340065/),,92.9,56929,DB00936,Salicylic acid
,11878089,Peak serum ASA concentrations (Cmax),Peak serum ASA concentrations (Cmax) were 6.8 mg/l for oral Lys-ASA and 2.7 mg/l for ASA per os.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),[mg] / [l],6.8,59082,DB00936,Salicylic acid
,11878089,Peak serum ASA concentrations (Cmax),Peak serum ASA concentrations (Cmax) were 6.8 mg/l for oral Lys-ASA and 2.7 mg/l for ASA per os.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),[mg] / [l],2.7,59083,DB00936,Salicylic acid
,11878089,tmax,The corresponding tmax-values were 14.2 and 38.0 min.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),min,14.2,59084,DB00936,Salicylic acid
,11878089,tmax,The corresponding tmax-values were 14.2 and 38.0 min.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),min,38.0,59085,DB00936,Salicylic acid
,11878089,Absolute bioavailabilities,"Absolute bioavailabilities for 500 mg doses were 75.4 and 63.4 pour cent, respectively.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),cent·pour,75.4,59086,DB00936,Salicylic acid
,11878089,Absolute bioavailabilities,"Absolute bioavailabilities for 500 mg doses were 75.4 and 63.4 pour cent, respectively.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),cent·pour,63.4,59087,DB00936,Salicylic acid
,11878089,Cmax,"After intake of 100 mg and 1000 mg oral doses of Lys-ASA Cmax was 2.7 mg/l and 15.9 mg/l, tmax being 14.2 min for the 1000 mg dose.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),[mg] / [l],2.7,59088,DB00936,Salicylic acid
,11878089,Cmax,"After intake of 100 mg and 1000 mg oral doses of Lys-ASA Cmax was 2.7 mg/l and 15.9 mg/l, tmax being 14.2 min for the 1000 mg dose.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),[mg] / [l],15.9,59089,DB00936,Salicylic acid
,11878089,tmax,"After intake of 100 mg and 1000 mg oral doses of Lys-ASA Cmax was 2.7 mg/l and 15.9 mg/l, tmax being 14.2 min for the 1000 mg dose.","[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),min,14.2,59090,DB00936,Salicylic acid
,11878089,half-life,The shortest half-life was found after i.v. injection with 7.5 min.,"[Pharmacokinetics after oral and intravenous administration of d,l-monolysine acetylsalicylate and an oral dose of acetylsalicylic acid in healthy volunteers]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11878089/),min,7.5,59091,DB00936,Salicylic acid
,24146062,peak serum concentrations,"After oral administration of 100 mg/kg b. w. (235.8 µmol/kg) salicortin to Wistar rats, peak serum concentrations of 1.43 mg/L (13.0 µM) catechol were detected after 0.5 h in addition to salicylic acid by HPLC-DAD after serum processing with β-glucuronidase and sulphatase.",Catechol conjugates are in vivo metabolites of Salicis cortex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24146062/),[mg] / [l],1.43,60479,DB00936,Salicylic acid
,24146062,cmax,"In humans, the cmax (1.46 mg/L, 13.3 µM) of catechol was reached after 1.2 h.",Catechol conjugates are in vivo metabolites of Salicis cortex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24146062/),[mg] / [l],1.46,60480,DB00936,Salicylic acid
,24146062,cmax,"In humans, the cmax (1.46 mg/L, 13.3 µM) of catechol was reached after 1.2 h.",Catechol conjugates are in vivo metabolites of Salicis cortex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24146062/),μM,13.3,60481,DB00936,Salicylic acid
,7180498,systemic availabilities,"For an effervescent, a plain and a sustained release preparation systemic availabilities expressed in percent of the ingested dose were 16.9 +/- 3.2, 8.6 +/- 1.2 and 2.6 +/- 0.4%, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),%,16.9,67383,DB00936,Salicylic acid
,7180498,systemic availabilities,"For an effervescent, a plain and a sustained release preparation systemic availabilities expressed in percent of the ingested dose were 16.9 +/- 3.2, 8.6 +/- 1.2 and 2.6 +/- 0.4%, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),%,8.6,67384,DB00936,Salicylic acid
,7180498,systemic availabilities,"For an effervescent, a plain and a sustained release preparation systemic availabilities expressed in percent of the ingested dose were 16.9 +/- 3.2, 8.6 +/- 1.2 and 2.6 +/- 0.4%, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),%,2.6,67385,DB00936,Salicylic acid
,7180498,peak concentration,All subjects had clearly measureable amounts of ASA in plasma after oral intake of a sustained release preparation with an average peak concentration of 15 mumol/l.,Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),[μM] / [l],15,67386,DB00936,Salicylic acid
,7180498,Peak concentration,"Peak concentration after an effervescent and plain formulation was on the average 80 and 40 mumol/l, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),[μM] / [l],80,67387,DB00936,Salicylic acid
,7180498,Peak concentration,"Peak concentration after an effervescent and plain formulation was on the average 80 and 40 mumol/l, respectively.",Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),[μM] / [l],40,67388,DB00936,Salicylic acid
,7180498,Half-life,Half-life of ASA in plasma was 18.1 +/- 1.2 min.,Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),min,18.1,67389,DB00936,Salicylic acid
,7180498,plasma half-life,Average plasma half-life of salicylic acid (SA) was similar after the three different administration forms with values between 3.0 and 3.7 hrs.,Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7180498/),h,3,67390,DB00936,Salicylic acid
greater,1874875,total urinary recovery,The total urinary recovery of salicylic acid after a single 1.2-g dose of soluble aspirin was greater than 90%.,Novel direct high-performance liquid chromatographic method for determination of salicylate glucuronide conjugates in human urine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1874875/),%,90,70883,DB00936,Salicylic acid
,18478192,maximum plasma concentration,The maximum plasma concentration of CAS was found to be 0.38 mg L(-1) with t (max) of 0.72 h.,Pharmacokinetic study of copper (II) acetylsalicylate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),[mg] / [l],0.38,73481,DB00936,Salicylic acid
,18478192,t (max),The maximum plasma concentration of CAS was found to be 0.38 mg L(-1) with t (max) of 0.72 h.,Pharmacokinetic study of copper (II) acetylsalicylate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),h,0.72,73482,DB00936,Salicylic acid
,18478192,plasma half-life,"The plasma half-life, clearance, and volume of distribution of CAS were 8.67 h, 66.30 L h(-1) and 829 L kg(-1), respectively.",Pharmacokinetic study of copper (II) acetylsalicylate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),h,8.67,73483,DB00936,Salicylic acid
,18478192,clearance,"The plasma half-life, clearance, and volume of distribution of CAS were 8.67 h, 66.30 L h(-1) and 829 L kg(-1), respectively.",Pharmacokinetic study of copper (II) acetylsalicylate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),[l] / [h],66.30,73484,DB00936,Salicylic acid
,18478192,volume of distribution,"The plasma half-life, clearance, and volume of distribution of CAS were 8.67 h, 66.30 L h(-1) and 829 L kg(-1), respectively.",Pharmacokinetic study of copper (II) acetylsalicylate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18478192/),[l] / [kg],829,73485,DB00936,Salicylic acid
,26168972,limit of detection (LOD),The limit of detection (LOD) was 8 mg/L and the lower limit of quantification (LLOQ) was 10 mg/L.,Personalized monitoring of therapeutic salicylic acid in dried blood spots using a three-layer setup and desorption electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26168972/),[mg] / [l],8,74798,DB00936,Salicylic acid
,26168972,Recovery rates,Recovery rates in method verification by LC-MS/MS were 97 to 101% for blinded samples.,Personalized monitoring of therapeutic salicylic acid in dried blood spots using a three-layer setup and desorption electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26168972/),%,97 to 101,74799,DB00936,Salicylic acid
,7061727,maximal plasma salicylate concentration (Cpmax),Both AC (44.16 +/- 16.85 microgram/ml) and AC + SS (58.61 +/- 10.63 microgram/ml) decreased (P less than 0.001) the maximal plasma salicylate concentration (Cpmax) compared to control (86.61 +/- 12.69 microgram/ml).,Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7061727/),[μg] / [ml],86.61,75596,DB00936,Salicylic acid
,7061727,recovery,"Urinary salicylate recovery was decreased (P less than 0.01) for AC (57.88 +/- 16.26 per cent) and AC + SS (61.00 +/- 11.49 per cent) as compared to control (93.73 +/- 6.83 per cent), while for area under the plasma concentration-time curve (AUC) only AC showed a decrease (P less than 0.01) compared to control.",Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7061727/),%,57.88,75597,DB00936,Salicylic acid
,7061727,recovery,"Urinary salicylate recovery was decreased (P less than 0.01) for AC (57.88 +/- 16.26 per cent) and AC + SS (61.00 +/- 11.49 per cent) as compared to control (93.73 +/- 6.83 per cent), while for area under the plasma concentration-time curve (AUC) only AC showed a decrease (P less than 0.01) compared to control.",Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7061727/),%,61.00,75598,DB00936,Salicylic acid
,7061727,recovery,"Urinary salicylate recovery was decreased (P less than 0.01) for AC (57.88 +/- 16.26 per cent) and AC + SS (61.00 +/- 11.49 per cent) as compared to control (93.73 +/- 6.83 per cent), while for area under the plasma concentration-time curve (AUC) only AC showed a decrease (P less than 0.01) compared to control.",Saline catharsis: effect on aspirin bioavailability in combination with activated charcoal. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7061727/),%,93.73,75599,DB00936,Salicylic acid
,3395669,Steady-state SA concentrations,Steady-state SA concentrations fell 23 per cent during the 4-week study period (mean +/- SD: 239 +/- 35 to 183 +/- 23 micrograms ml-1; p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[μg] / [ml],239,76907,DB00936,Salicylic acid
,3395669,Steady-state SA concentrations,Steady-state SA concentrations fell 23 per cent during the 4-week study period (mean +/- SD: 239 +/- 35 to 183 +/- 23 micrograms ml-1; p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[μg] / [ml],183,76908,DB00936,Salicylic acid
,3395669,Vmax SU,Mean Vmax SU increased from 0.93 to 1.68 mg kg-1 h-1 (p less than 0.05) and mean Vmax SPG increased from 0.09 to 0.19 mg kg-1 h-1 (p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[mg] / [h·kg],0.93,76909,DB00936,Salicylic acid
,3395669,Vmax SU,Mean Vmax SU increased from 0.93 to 1.68 mg kg-1 h-1 (p less than 0.05) and mean Vmax SPG increased from 0.09 to 0.19 mg kg-1 h-1 (p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[mg] / [h·kg],1.68,76910,DB00936,Salicylic acid
,3395669,Vmax SPG,Mean Vmax SU increased from 0.93 to 1.68 mg kg-1 h-1 (p less than 0.05) and mean Vmax SPG increased from 0.09 to 0.19 mg kg-1 h-1 (p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[mg] / [h·kg],0.09,76911,DB00936,Salicylic acid
,3395669,Vmax SPG,Mean Vmax SU increased from 0.93 to 1.68 mg kg-1 h-1 (p less than 0.05) and mean Vmax SPG increased from 0.09 to 0.19 mg kg-1 h-1 (p less than 0.05).,Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395669/),[mg] / [h·kg],0.19,76912,DB00936,Salicylic acid
,1977396,Recovery,Recovery of the analytical substances ranged from 82.7% for paracetamol to 98.5% for salicylic acid.,High-pressure liquid chromatographic evaluation of cyclic paracetamol-acetylsalicylate and its active metabolites with results of a comparative pharmacokinetic investigation in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1977396/),%,82.7,77492,DB00936,Salicylic acid
,1977396,Recovery,Recovery of the analytical substances ranged from 82.7% for paracetamol to 98.5% for salicylic acid.,High-pressure liquid chromatographic evaluation of cyclic paracetamol-acetylsalicylate and its active metabolites with results of a comparative pharmacokinetic investigation in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1977396/),%,98.5,77493,DB00936,Salicylic acid
,11955805,T(max),"The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),h,6,78533,DB00936,Salicylic acid
,11955805,T(max),"The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),h,5,78534,DB00936,Salicylic acid
,11955805,area under the curve (AUC),"The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),%,69.37,78535,DB00936,Salicylic acid
,11955805,area under the curve (AUC),"The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),%,57.98,78536,DB00936,Salicylic acid
,11955805,AUC,Formulation of insulin with sodium salicylate in PEG 4000 produced a lower AUC of 37.30+/-10.36% red. h and RH of 4.69+/-1.3%.,Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),%·h·red,37.30,78537,DB00936,Salicylic acid
,11955805,T(max),It produced 25% reduction in plasma glucose levels of the hyperglycemic beagle dogs at T(max) of 4 h and the largest AUC of 100.10+/-25.72% red.,Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),h,4,78538,DB00936,Salicylic acid
,11955805,RH,"h, resulting in the highest RH of 12.59+/-3.23%.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),%,12,78539,DB00936,Salicylic acid
,6533283,distribution volume,The distribution volume of salicylic acid in analbuminemic rats (650 +/- 33 ml/kg) was remarkably larger than that in normal rats (180 +/- 3 ml/kg) (p less than 0.01).,Disposition of salicylic acid in analbuminemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533283/),[ml] / [kg],650,79304,DB00936,Salicylic acid
,6533283,distribution volume,The distribution volume of salicylic acid in analbuminemic rats (650 +/- 33 ml/kg) was remarkably larger than that in normal rats (180 +/- 3 ml/kg) (p less than 0.01).,Disposition of salicylic acid in analbuminemic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533283/),[ml] / [kg],180,79305,DB00936,Salicylic acid
,6533283,total body clearance,"The total body clearance of salicylic acid in analbuminemic rats (12.2 +/- 1.4 ml/min/kg) was about 3.2 times that in normal rats (3.8 +/- 0.1 ml/min/kg) (p less than 0.01), suggesting that metabolic clearance and/or renal clearance is enhanced in analbuminemic rats.",Disposition of salicylic acid in analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533283/),[ml] / [kg·min],12.2,79306,DB00936,Salicylic acid
,6533283,total body clearance,"The total body clearance of salicylic acid in analbuminemic rats (12.2 +/- 1.4 ml/min/kg) was about 3.2 times that in normal rats (3.8 +/- 0.1 ml/min/kg) (p less than 0.01), suggesting that metabolic clearance and/or renal clearance is enhanced in analbuminemic rats.",Disposition of salicylic acid in analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6533283/),[ml] / [kg·min],3.8,79307,DB00936,Salicylic acid
,1970771,steady state plasma level,A 50 mg/kg bolus dose of sodium valproate was injected iv to Long Evans rats with and without (control) prior treatment by constant infusion of salicylate to keep it at steady state plasma level (about 250 micrograms/ml).,Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970771/),[μg] / [ml],250,81159,DB00936,Salicylic acid
,1970771,apparent dissociation constant,The apparent dissociation constant of plasma protein binding for valproic acid was increased from 0.287 to 1.204 mM in the presence of salicylic acid.,Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970771/),mM,0.287,81160,DB00936,Salicylic acid
,1970771,apparent dissociation constant,The apparent dissociation constant of plasma protein binding for valproic acid was increased from 0.287 to 1.204 mM in the presence of salicylic acid.,Drug interaction. Effects of salicylate on pharmacokinetics of valproic acid in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970771/),mM,1.204,81161,DB00936,Salicylic acid
,2072775,time elapsed to achieve maximum plasma concentrations in,"The time elapsed to achieve maximum plasma concentrations in the systemic circulation was 1 to 4 hours, as compared with 0.25 to 1.5 hours with other conventional preparations of ASA.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),h,1 to 4,81368,DB00936,Salicylic acid
,2072775,time elapsed to achieve maximum plasma concentrations in,"The time elapsed to achieve maximum plasma concentrations in the systemic circulation was 1 to 4 hours, as compared with 0.25 to 1.5 hours with other conventional preparations of ASA.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),h,0.25 to 1.5,81369,DB00936,Salicylic acid
,2072775,maximum plasma concentration,"The maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as compared with 4.8, 12, and 14 micrograms/ml with other preparations.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),[μg] / [ml],1.2,81370,DB00936,Salicylic acid
,2072775,maximum plasma concentration,"The maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as compared with 4.8, 12, and 14 micrograms/ml with other preparations.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),[μg] / [ml],4.8,81371,DB00936,Salicylic acid
,2072775,maximum plasma concentration,"The maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as compared with 4.8, 12, and 14 micrograms/ml with other preparations.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),[μg] / [ml],12,81372,DB00936,Salicylic acid
,2072775,maximum plasma concentration,"The maximum plasma concentration recorded in one subject was 1.2 micrograms/ml, as compared with 4.8, 12, and 14 micrograms/ml with other preparations.",[Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072775/),[μg] / [ml],14,81373,DB00936,Salicylic acid
,17694544,maximum SA concentration (Cmax),The mean (SD) maximum SA concentration (Cmax) was 0.81 (0.32) microg/mL and 56.4 (14.2) microg/mL.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),[μg] / [ml],0.81,84221,DB00936,Salicylic acid
,17694544,maximum SA concentration (Cmax),The mean (SD) maximum SA concentration (Cmax) was 0.81 (0.32) microg/mL and 56.4 (14.2) microg/mL.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),[μg] / [ml],56.4,84222,DB00936,Salicylic acid
,17694544,safety margin ratio,The AUC-based safety margin ratio was 50:1.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),,50,84223,DB00936,Salicylic acid
,17694544,Cmax,Plasma SA Cmax values were achieved from 1.4 to 3.5 h after topical application and from 0.5 to 1.5 h after oral aspirin.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),h,1.4 to 3.5,84224,DB00936,Salicylic acid
,17694544,Cmax,Plasma SA Cmax values were achieved from 1.4 to 3.5 h after topical application and from 0.5 to 1.5 h after oral aspirin.,Relative bioavailability of salicylic acid following dermal application of a 30% salicylic acid skin peel preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17694544/),h,0.5 to 1.5,84225,DB00936,Salicylic acid
,8750369,Peak plasma ASA levels,Peak plasma ASA levels of 1 microgram/mL were achieved within 30 minutes.,Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750369/),[μg] / [ml],1,84915,DB00936,Salicylic acid
,8750369,Peak plasma SA levels,Peak plasma SA levels of approximately 4 micrograms/mL were attained in 1 hour.,Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750369/),[μg] / [ml],4,84916,DB00936,Salicylic acid
,8750369,terminal half-lives (t1/2),"The terminal half-lives (t1/2) of ASA and SA were 0.4 and 2.1 hours, respectively.",Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750369/),h,0.4,84917,DB00936,Salicylic acid
,8750369,terminal half-lives (t1/2),"The terminal half-lives (t1/2) of ASA and SA were 0.4 and 2.1 hours, respectively.",Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750369/),h,2.1,84918,DB00936,Salicylic acid
,3680588,peak concentration,"The mean peak concentration of aspirin was 6.5 micrograms/mL in plasma (range, 4.9-8.9 micrograms/mL), reached in 26 minutes (range, 13-33 minutes).",Disposition of aspirin and its metabolites in the semen of man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),[μg] / [ml],6.5,85256,DB00936,Salicylic acid
,3680588,half-life,The half-life of aspirin was 31 minutes.,Disposition of aspirin and its metabolites in the semen of man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),min,31,85257,DB00936,Salicylic acid
,3680588,peak concentration,"The mean peak concentration of salicylate in plasma was 49 micrograms/mL (range, 42-62 micrograms/mL), reached in 2.5 hours (range, 2.0-2.8 hours).",Disposition of aspirin and its metabolites in the semen of man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),[μg] / [ml],49,85258,DB00936,Salicylic acid
,3680588,concentration ratio,Salicylate distributed rapidly into semen and maintained a concentration ratio (semen/plasma) of 0.15.,Disposition of aspirin and its metabolites in the semen of man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680588/),,0.15,85259,DB00936,Salicylic acid
,23906222,mean residence time (MRT),"2. The mean residence time (MRT) of salicylate (SA) after i.v. administration of SS was 6.08 ± 0.59 and 3.32 ± 0.27 h and after oral administration was 6.95 ± 0.72 and 4.55 ± 0.71 h in chickens and turkeys, respectively.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,6.08,86751,DB00936,Salicylic acid
,23906222,mean residence time (MRT),"2. The mean residence time (MRT) of salicylate (SA) after i.v. administration of SS was 6.08 ± 0.59 and 3.32 ± 0.27 h and after oral administration was 6.95 ± 0.72 and 4.55 ± 0.71 h in chickens and turkeys, respectively.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,3.32,86752,DB00936,Salicylic acid
,23906222,mean residence time (MRT),"2. The mean residence time (MRT) of salicylate (SA) after i.v. administration of SS was 6.08 ± 0.59 and 3.32 ± 0.27 h and after oral administration was 6.95 ± 0.72 and 4.55 ± 0.71 h in chickens and turkeys, respectively.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,6.95,86753,DB00936,Salicylic acid
,23906222,mean residence time (MRT),"2. The mean residence time (MRT) of salicylate (SA) after i.v. administration of SS was 6.08 ± 0.59 and 3.32 ± 0.27 h and after oral administration was 6.95 ± 0.72 and 4.55 ± 0.71 h in chickens and turkeys, respectively.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,4.55,86754,DB00936,Salicylic acid
,23906222,maximal plasma concentration of SA (C max),"The bioavailability of SS was complete and the maximal plasma concentration of SA (C max) after oral administration was 96.93 ± 8.06 and 91.76 ± 9.64 µg/ml, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],96.93,86755,DB00936,Salicylic acid
,23906222,maximal plasma concentration of SA (C max),"The bioavailability of SS was complete and the maximal plasma concentration of SA (C max) after oral administration was 96.93 ± 8.06 and 91.76 ± 9.64 µg/ml, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],91.76,86756,DB00936,Salicylic acid
,23906222,MRT,"3. The MRT of ASA after iv administration was 0.24 ± 0.08 and 0.24 ± 0.02 h and after oral administration was 0.78 ± 0.25 and 0.59 ± 0.13 h, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,0.24,86757,DB00936,Salicylic acid
,23906222,MRT,"3. The MRT of ASA after iv administration was 0.24 ± 0.08 and 0.24 ± 0.02 h and after oral administration was 0.78 ± 0.25 and 0.59 ± 0.13 h, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,0.24,86758,DB00936,Salicylic acid
,23906222,MRT,"3. The MRT of ASA after iv administration was 0.24 ± 0.08 and 0.24 ± 0.02 h and after oral administration was 0.78 ± 0.25 and 0.59 ± 0.13 h, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,0.78,86759,DB00936,Salicylic acid
,23906222,MRT,"3. The MRT of ASA after iv administration was 0.24 ± 0.08 and 0.24 ± 0.02 h and after oral administration was 0.78 ± 0.25 and 0.59 ± 0.13 h, respectively, in chickens and turkeys.",Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),h,0.59,86760,DB00936,Salicylic acid
,23906222,bioavailability,The bioavailability of unchanged ASA was low and C max after oral administration was 6.9 ± 3.6 µg/ml in chickens and 8.6 ± 1.3 µg/ml in turkeys.,Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],6.9,86761,DB00936,Salicylic acid
,23906222,C max,The bioavailability of unchanged ASA was low and C max after oral administration was 6.9 ± 3.6 µg/ml in chickens and 8.6 ± 1.3 µg/ml in turkeys.,Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],6.9,86762,DB00936,Salicylic acid
,23906222,C max,The bioavailability of unchanged ASA was low and C max after oral administration was 6.9 ± 3.6 µg/ml in chickens and 8.6 ± 1.3 µg/ml in turkeys.,Comparative pharmacokinetics of acetylsalicylic acid and sodium salicylate in chickens and turkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23906222/),[μg] / [ml],8.6,86763,DB00936,Salicylic acid
,7514021,total body clearance,"For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively.",Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514021/),[ml] / [kg·min],37.9,87913,DB00936,Salicylic acid
,7514021,total body clearance,"For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively.",Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514021/),[ml] / [kg·min],38.5,87914,DB00936,Salicylic acid
,7514021,volume of distribution (Vd),"For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively.",Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514021/),[ml] / [kg],385.5,87915,DB00936,Salicylic acid
,7514021,volume of distribution (Vd),"For instance, the total body clearance for ASA (mean +/- SD, mL/min/kg) was 37.9 +/- 9.4 and 38.5 +/- 13.9 (p > 0.05); and the volume of distribution (Vd) for ASA (mean +/- SD, mL/kg) was 385.5 +/- 110.3 and 397.1.1 +/- 137.9 (p > 0.05) for CuD and CuS groups, respectively.",Pharmacokinetics and pharmacodynamics in copper deficiency. I. Antiinflammatory activity of aspirin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7514021/),[ml] / [kg],397.1.1,87916,DB00936,Salicylic acid
,6470965,"""trough"" concentrations","Mean ""trough"" concentrations fell within the therapeutic range (5-30 mg/dL) with either regimen and were relatively constant, indicating that the steady state had been reached.",Choline magnesium trisalicylate: comparative pharmacokinetic study of once-daily and twice-daily dosages. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470965/),[mg] / [dl],5-30,89209,DB00936,Salicylic acid
,23777611,total run time,The total run time was only 5.0min.,"Application of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of brazilin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777611/),min,5.0,89260,DB00936,Salicylic acid
,23777611,Recoveries,Recoveries (78.9-93.8%) and matrix effects (81.0-97.8%) were satisfactory in all the biological matrices examined.,"Application of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of brazilin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777611/),%,78.9-93.8,89261,DB00936,Salicylic acid
,11978144,half-life,"Following intravitreal administration, fomivirsen is slowly cleared from vitreous with a half-life of approximately 55 hours in humans.",Fomivirsen: clinical pharmacology and potential drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978144/),h,55,90169,DB00936,Salicylic acid
,11978144,half-life for clearance,The estimated half-life for clearance of fomivirsen from retina was 78 hours in monkeys following a 115-microg dose.,Fomivirsen: clinical pharmacology and potential drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978144/),h,78,90170,DB00936,Salicylic acid
,28103874,maximum concentrations,"In the 25 mg/kg group, maximum concentrations were detected after 2 h (urine, 2785 μg/mL) and 1.5 h (plasma, 23 μg/mL).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],2785,90639,DB00936,Salicylic acid
,28103874,maximum concentrations,"In the 25 mg/kg group, maximum concentrations were detected after 2 h (urine, 2785 μg/mL) and 1.5 h (plasma, 23 μg/mL).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],23,90640,DB00936,Salicylic acid
,28103874,maximum concentrations,"In the 50 mg/kg group, maximum concentrations were observed after 5 h (urine, 3915 μg/mL) and 1.5 h (plasma, 45 μg/mL).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],3915,90641,DB00936,Salicylic acid
,28103874,maximum concentrations,"In the 50 mg/kg group, maximum concentrations were observed after 5 h (urine, 3915 μg/mL) and 1.5 h (plasma, 45 μg/mL).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],45,90642,DB00936,Salicylic acid
,28103874,plasma half-life,The plasma half-life calculated for SA varied between 5.0 and 5.7 h.,Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),h,5.0 and 5.7,90643,DB00936,Salicylic acid
,28103874,IC50,"For ASA, IC50 were 0.50 μg/mL (COX-1) and 5.14 μg/mL (COX-2).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],0.50,90644,DB00936,Salicylic acid
,28103874,IC50,"For ASA, IC50 were 0.50 μg/mL (COX-1) and 5.14 μg/mL (COX-2).",Pharmacokinetics and in vitro efficacy of salicylic acid after oral administration of acetylsalicylic acid in horses. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28103874/),[μg] / [ml],5.14,90645,DB00936,Salicylic acid
above,2609979,Recoveries,Recoveries of salicylic acid were found to be above 98.4% and the method was linear from 8-160 micrograms with a correlation coefficient of 0.9999.,[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),%,98.4,91918,DB00936,Salicylic acid
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),h,2.3374,91919,DB00936,Salicylic acid
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),h,0.9846,91920,DB00936,Salicylic acid
,2609979,T1/2 (beta),"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],157.71,91921,DB00936,Salicylic acid
,2609979,AUC0-infinity,"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],361.63,91922,DB00936,Salicylic acid
,2609979,AUC0-infinity,"Among the pharmacokinetic parameters of NA, T1/2 (beta) and AUC0-infinity for the group (n = 6) treated with NA 50 mg/kg in combination with ASA 50 mg/kg were 2.3374 h and 361.63 micrograms.h/ml, respectively, both significantly different from those for the group (n = 6) treated with NA 50 mg/kg alone which were 0.9846 h and 157.71 micrograms.h/ml, respectively (p less than 0.01).",[Determination of aspirin and nicotinic acid in plasma when used in combination]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2609979/),[h·μg] / [ml],157.71,91923,DB00936,Salicylic acid
,25402445,Tmax,Acetylsalicylic acid was rapidly absorbed with a mean Tmax of 27 ± 8 min.,Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402445/),min,27,92499,DB00936,Salicylic acid
,25402445,Tmax,Tmax of salicylic acid was 69 ± 21 min.,Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402445/),min,69,92500,DB00936,Salicylic acid
,25402445,Cmax,"Mean Cmax was 1·8 ± 0·6 mg/L and 7·6 ± 1·4 for acetylsalicylic acid and salicylic acid, respectively.",Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402445/),[mg] / [l],1·8,92501,DB00936,Salicylic acid
,25402445,Cmax,"Mean Cmax was 1·8 ± 0·6 mg/L and 7·6 ± 1·4 for acetylsalicylic acid and salicylic acid, respectively.",Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25402445/),,7·6,92502,DB00936,Salicylic acid
,11642382,maximum blood plasma levels,The maximum blood plasma levels were 5.2 microg/mL.,Slow release of acetylsalicylic acid by intravitreal silicone oil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11642382/),[μg] / [ml],5.2,92547,DB00936,Salicylic acid
,18254152,m,"The ion transitions recorded in multiple reaction monitoring mode were m/z 179 --> 137, 137 --> 93 and 435 --> 319 for ASA, SA and IS, respectively.","Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study of Astrix in Korean healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254152/),,179,92858,DB00936,Salicylic acid
,2777424,tmax,Results indicated no statistical differences in any of the kinetic parameters studied except for tmax values which were higher for fosfosal combined with codeine (2 +/- 0.39 h) when compared to fosfosal alone (1.55 +/- 0.35 h).,Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,2,93414,DB00936,Salicylic acid
,2777424,tmax,Results indicated no statistical differences in any of the kinetic parameters studied except for tmax values which were higher for fosfosal combined with codeine (2 +/- 0.39 h) when compared to fosfosal alone (1.55 +/- 0.35 h).,Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,1.55,93415,DB00936,Salicylic acid
,2777424,tmax,"Regarding codeine compared in combination with fosfosal, no significant differences were observed in Cmax and AUC values, while tmax showed a higher value for the combination (1.75 +/- 0.6 vs 0.85 +/- 0.32 h).",Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,1.75,93416,DB00936,Salicylic acid
,2777424,tmax,"Regarding codeine compared in combination with fosfosal, no significant differences were observed in Cmax and AUC values, while tmax showed a higher value for the combination (1.75 +/- 0.6 vs 0.85 +/- 0.32 h).",Bioavailability study of fosfosal and codeine administered alone or in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2777424/),h,0.85,93417,DB00936,Salicylic acid
,3264273,steady state plasma concentrations,"In this study, pharmacokinetic evaluation of fosfosal after a single 2,400 mg and three different oral dose schedules (1,200 mg t.i.d., 2,400 mg b.i.d. and 2,400 mg t.i.d.) was carried out, in six healthy male volunteers, to assess which doses provide steady state plasma concentrations within the therapeutic range (150-300 micrograms/ml).",Pharmacokinetics of fosfosal after single and multiple oral doses in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264273/),[μg] / [ml],150-300,93479,DB00936,Salicylic acid
,3264273,Cmin-ss,"For the 2,400 mg t.i.d., Cmin-ss and Cmax-ss values were 184 micrograms/ml and 276 micrograms/ml, respectively, being significantly higher (p less than 0.02) than with the other regimes and, unlike the latter, falling within the anti-inflammatory therapeutic range.",Pharmacokinetics of fosfosal after single and multiple oral doses in man. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264273/),[μg] / [ml],184,93480,DB00936,Salicylic acid
,3264273,Cmax-ss,"For the 2,400 mg t.i.d., Cmin-ss and Cmax-ss values were 184 micrograms/ml and 276 micrograms/ml, respectively, being significantly higher (p less than 0.02) than with the other regimes and, unlike the latter, falling within the anti-inflammatory therapeutic range.",Pharmacokinetics of fosfosal after single and multiple oral doses in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264273/),[μg] / [ml],276,93481,DB00936,Salicylic acid
,8876850,Cmax,"However, concentrations between 0.31 and 0.91 mg/L were detected within 1 hour of the first application of methyl salicylate and Cmax between 2 and 6 mg/L were observed following the seventh application on day 4.",Serum concentrations of salicylic acid following topically applied salicylate derivatives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876850/),[mg] / [l],2 and 6,93552,DB00936,Salicylic acid
,8876850,absorption rate constant,"The absorption rate constant increased significantly from the first to the seventh dose (first dose absorption rate constant: 0.16 h-1, seventh dose: 0.28 h-1; p < 0.035).",Serum concentrations of salicylic acid following topically applied salicylate derivatives. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876850/),1/[h],0.16,93553,DB00936,Salicylic acid
,8876850,absorption rate constant,"The absorption rate constant increased significantly from the first to the seventh dose (first dose absorption rate constant: 0.16 h-1, seventh dose: 0.28 h-1; p < 0.035).",Serum concentrations of salicylic acid following topically applied salicylate derivatives. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876850/),1/[h],0.28,93554,DB00936,Salicylic acid
,8876850,Urinary recovery,"Urinary recovery of total salicylate (salicylic acid and principal metabolites of salicylic acid) during the first 24 hours of the methyl salicylate phase averaged 175.2 mg, exceeding the 6.9 mg (p < 0.05) recovered during the trolamine phase.",Serum concentrations of salicylic acid following topically applied salicylate derivatives. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876850/),mg,175.2,93555,DB00936,Salicylic acid
,8876850,Urinary recovery,"Urinary recovery of total salicylate (salicylic acid and principal metabolites of salicylic acid) during the first 24 hours of the methyl salicylate phase averaged 175.2 mg, exceeding the 6.9 mg (p < 0.05) recovered during the trolamine phase.",Serum concentrations of salicylic acid following topically applied salicylate derivatives. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8876850/),mg,6.9,93556,DB00936,Salicylic acid
,7900541,dissolution rates,The dissolution rates of ground and unground drug are 0.0337 min-1 and 0.0152 min-1 (P < 0.001) respectively.,[Studies on formulation and bioavailability of benorilate tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),1/[min],0.0337,94168,DB00936,Salicylic acid
,7900541,dissolution rates,The dissolution rates of ground and unground drug are 0.0337 min-1 and 0.0152 min-1 (P < 0.001) respectively.,[Studies on formulation and bioavailability of benorilate tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),1/[min],0.0152,94169,DB00936,Salicylic acid
,7900541,mean dissolution time,The mean dissolution time of B and A are 15.77 min and 42.25 min (P < 0.001) respectively.,[Studies on formulation and bioavailability of benorilate tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),min,15.77,94170,DB00936,Salicylic acid
,7900541,mean dissolution time,The mean dissolution time of B and A are 15.77 min and 42.25 min (P < 0.001) respectively.,[Studies on formulation and bioavailability of benorilate tablets]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),min,42.25,94171,DB00936,Salicylic acid
,7900541,relative bioavailability,The relative bioavailability of B to A is 125.59%.,[Studies on formulation and bioavailability of benorilate tablets]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7900541/),%,125.59,94172,DB00936,Salicylic acid
,3181281,maximum concentration (Cmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[ng] / [ml],221,96093,DB00936,Salicylic acid
,3181281,maximum concentration (Cmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[ng] / [ml],191,96094,DB00936,Salicylic acid
,3181281,maximum concentration (Cmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[ng] / [ml],1323,96095,DB00936,Salicylic acid
,3181281,maximum concentration (Cmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[ng] / [ml],6000,96096,DB00936,Salicylic acid
,3181281,time to achieve this maximum concentration (tmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),h,3.42,96097,DB00936,Salicylic acid
,3181281,time to achieve this maximum concentration (tmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),h,3.02,96098,DB00936,Salicylic acid
,3181281,time to achieve this maximum concentration (tmax,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),h,0.29,96099,DB00936,Salicylic acid
,3181281,area under the plasma drug concentration versus time curve (AUC,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[h·μg] / [ml],0.38,96100,DB00936,Salicylic acid
,3181281,area under the plasma drug concentration versus time curve (AUC,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[h·μg] / [ml],0.27,96101,DB00936,Salicylic acid
,3181281,area under the plasma drug concentration versus time curve (AUC,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[h·μg] / [ml],0.68,96102,DB00936,Salicylic acid
,3181281,area under the plasma drug concentration versus time curve (AUC,"The formulation and route of administration profoundly influenced several pharmacokinetic parameters for aspirin: the maximum concentration (Cmax, ng.ml-1) was 221 and 191 after modified release for single and chronic dosing respectively, 1323 after the oral solution and 6000 after intravenous injection; the time to achieve this maximum concentration (tmax, h) was 3.42 and 3.02 after modified release for single and chronic dosing respectively, and 0.29 after the oral solution; the area under the plasma drug concentration versus time curve (AUC, microgram.h.ml-1) was 0.38 and 0.27 after modified release single and chronic dosing respectively, 0.68 after the oral solution and 1.57 after intravenous injection.","Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),[h·μg] / [ml],1.57,96103,DB00936,Salicylic acid
,3181281,terminal phase rate constant,The terminal phase rate constant ranged from 1.52 h-1 after intravenous injection to 1.88 h-1 after the oral modified release form.,"Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),1/[h],1.52,96104,DB00936,Salicylic acid
,3181281,terminal phase rate constant,The terminal phase rate constant ranged from 1.52 h-1 after intravenous injection to 1.88 h-1 after the oral modified release form.,"Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3181281/),1/[h],1.88,96105,DB00936,Salicylic acid
,11689002,bound fraction of,"Binding assays of studied compounds to purified 1% (w/v) HSA at 0 degrees C, indicate that bound fraction of 2-7 ranges from 13 to 47%, exhibiting a higher affinity to HSA than AZT (12%), which would introduce some interesting improvements in their pharmacokinetic properties.",Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689002/),%,13 to 47,96817,DB00936,Salicylic acid
,11689002,DeltaS,"In addition, by means of displacement studies using HSA site specific drugs such as diazepam and salicylate, it was determined that AZT binds to site I of the HSA molecule, by a mainly entropy driven process (DeltaS = 10.834 cal/mol degrees K), being these observations extensive to 2-7.",Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11689002/),[cal] / [degrees·k·mol],10.834,96818,DB00936,Salicylic acid
,713432,half-life,Elimination of acetylsalicylic acid was relatively quick within the first period after intravenous administration according to a half-life of 8 minutes.,Pharmacokinetic investigations in adult humans after parenteral administration of the lysine salt of acetyl-salicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/713432/),min,8,97339,DB00936,Salicylic acid
,713432,Half-life,Half-life of salicylic acid was determined to be 3 hours.,Pharmacokinetic investigations in adult humans after parenteral administration of the lysine salt of acetyl-salicylic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/713432/),h,3,97340,DB00936,Salicylic acid
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],16.1,99215,DB00936,Salicylic acid
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],13.7,99216,DB00936,Salicylic acid
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,25.5,99217,DB00936,Salicylic acid
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,33.3,99218,DB00936,Salicylic acid
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,97.5,99219,DB00936,Salicylic acid
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,95.1,99220,DB00936,Salicylic acid
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,347.6,99221,DB00936,Salicylic acid
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],5.34,99222,DB00936,Salicylic acid
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],6.30,99223,DB00936,Salicylic acid
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.91,99224,DB00936,Salicylic acid
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,633,99225,DB00936,Salicylic acid
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,78.7,99226,DB00936,Salicylic acid
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.05,99227,DB00936,Salicylic acid
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.27,99228,DB00936,Salicylic acid
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],11.2,99229,DB00936,Salicylic acid
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.92,99230,DB00936,Salicylic acid
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,9.7,99231,DB00936,Salicylic acid
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,32.5,99232,DB00936,Salicylic acid
,3956057,peak plasma SSA level,"Compared with control subjects, patients undergoing dialysis had a lower peak plasma SSA level (17 +/- 3 vs. 45 +/- 2 micrograms/ml; P less than 0.01) that occurred slightly later.",Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956057/),[μg] / [ml],17,102391,DB00936,Salicylic acid
,3956057,peak plasma SSA level,"Compared with control subjects, patients undergoing dialysis had a lower peak plasma SSA level (17 +/- 3 vs. 45 +/- 2 micrograms/ml; P less than 0.01) that occurred slightly later.",Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956057/),[μg] / [ml],45,102392,DB00936,Salicylic acid
,3956057,t1/2,"Therefore, the AUC for SA was increased by 50% and the SA t1/2 was prolonged in the patients receiving dialysis (8.1 +/- 0.7 vs 3.8 +/- 0.2 hours; P less than 0.01).",Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956057/),h,8.1,102393,DB00936,Salicylic acid
,3956057,t1/2,"Therefore, the AUC for SA was increased by 50% and the SA t1/2 was prolonged in the patients receiving dialysis (8.1 +/- 0.7 vs 3.8 +/- 0.2 hours; P less than 0.01).",Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956057/),h,3.8,102394,DB00936,Salicylic acid
,17610403,V(d(ss)),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[l] / [kg],0.18,103021,DB00936,Salicylic acid
,17610403,Cl(B),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[ml] / [kg·min],3.36,103022,DB00936,Salicylic acid
,17610403,t(1/2 lambda),"Intravenous salicylate V(d(ss)) was 0.18 L/kg, Cl(B) was 3.36 mL/min/kg and t(1/2 lambda) was 0.63 h.",Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),h,0.63,103023,DB00936,Salicylic acid
<,17610403,Peak salicylate concentrations,Peak salicylate concentrations following oral aspirin administration was <10 microg/mL and failed to attenuate cortisol response.,Attenuation of acute plasma cortisol response in calves following intravenous sodium salicylate administration prior to castration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610403/),[μg] / [ml],10,103024,DB00936,Salicylic acid
,14716871,relative bioavailability,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),%,105.36,103520,DB00936,Salicylic acid
,14716871,AUC0-T,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),[h·μg] / [ml],103.10,103521,DB00936,Salicylic acid
,14716871,AUC0-T,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),[h·μg] / [ml],98.45,103522,DB00936,Salicylic acid
,14716871,Tmax,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),h,1.5,103523,DB00936,Salicylic acid
,14716871,Cmax,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),[μg] / [ml],19.31,103524,DB00936,Salicylic acid
,14716871,Cmax,The relative bioavailability of salicylic acid was 105.36% +/- 14.15%; AUC0-T of salicylic acid of test and reference preparations were 103.10 +/- 11.92 micrograms.h/ml and 98.45 +/- 13.49 micrograms.h/ml respectively; Tmax were 1.5 +/- 0.5 h and 1.5 +/- 0.5 h; Cmax were 19.31 +/- 2.47 micrograms/ml and 18.95 +/- 2.49 micrograms/ml.,[Study on relative bioavailability of aspirin in afenca tablet]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14716871/),[μg] / [ml],18.95,103525,DB00936,Salicylic acid
,17360832,t1/2,"The average CP-122,721 t1/2 was 6.7 h and 45.0 h for EM and PM subjects, respectively.","Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17360832/),h,6.7,104841,DB00936,Salicylic acid
,17360832,t1/2,"The average CP-122,721 t1/2 was 6.7 h and 45.0 h for EM and PM subjects, respectively.","Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17360832/),h,45.0,104842,DB00936,Salicylic acid
,17360832,peak,"The serum concentrations of CP-122,721 reached a peak of 7.4 and 69.8 ng/ml for extensive and poor metabolizers, respectively.","Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17360832/),[ng] / [ml],7.4,104843,DB00936,Salicylic acid
,17360832,peak,"The serum concentrations of CP-122,721 reached a peak of 7.4 and 69.8 ng/ml for extensive and poor metabolizers, respectively.","Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17360832/),[ng] / [ml],69.8,104844,DB00936,Salicylic acid
,16013036,flow rate,The chromatographic separation was achieved by gradient elution consisting of 0.05 M formic acid (pH 3)-acetonitrile-methanol-water at a flow rate of 1.0 mL/min.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),[ml] / [min],1.0,105998,DB00936,Salicylic acid
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,15.63,105999,DB00936,Salicylic acid
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,17.20,106000,DB00936,Salicylic acid
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,21.66,106001,DB00936,Salicylic acid
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,24.95,106002,DB00936,Salicylic acid
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,26.27,106003,DB00936,Salicylic acid
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,30.24,106004,DB00936,Salicylic acid
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,32.22,106005,DB00936,Salicylic acid
>,16013036,Absolute recovery,Absolute recovery was >83% from human plasma for all the analytes and IS.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),%,83,106006,DB00936,Salicylic acid
over,9521569,recovery,A linear response to quantities of ASA from 0.1 to 100 microg/cm2 and of SA from 0.1 to 5 microg/cm2 in tape and to quantities of ASA 0.1 to 2 microg/ml and 1 to 50 microg/ml was obtained and the recovery from tape and plasma samples was over 98%.,Determination of acetylsalicylic acid and salicylic acid in skin and plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521569/),%,98,107314,DB00936,Salicylic acid
,2386326,Recovery,"Recovery of sodium salicylate and SUA in goats amounted to 67.9 and 34.6% of the dose, respectively, after IV administration.",Elimination of salicylic acid in goats and cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386326/),%,67.9,107937,DB00936,Salicylic acid
,2386326,Recovery,"Recovery of sodium salicylate and SUA in goats amounted to 67.9 and 34.6% of the dose, respectively, after IV administration.",Elimination of salicylic acid in goats and cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386326/),%,34.6,107938,DB00936,Salicylic acid
,2386326,total recoveries,"After oral dosing, total recoveries were 30.2% (sodium salicylate) and 71.7% (SUA) of dose.",Elimination of salicylic acid in goats and cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386326/),%,30.2,107939,DB00936,Salicylic acid
,2386326,total recoveries,"After oral dosing, total recoveries were 30.2% (sodium salicylate) and 71.7% (SUA) of dose.",Elimination of salicylic acid in goats and cattle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2386326/),%,71.7,107940,DB00936,Salicylic acid
,24312851,AUC0-8hr,"Median (% of interquartile range/median) of salicylic acid AUC0-8hr (ng/mL/hr) values in Transcutol(®) or eucalyptus oil treated rats were 2522(139%) and 58976(141%), respectively as compared to the 3023(327%) of the control group.",Percutaneous absorption of salicylic Acid after administration of trolamine salicylate cream in rats with transcutol(®) and eucalyptus oil pre-treated skin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24312851/),[ng] / [h·ml],2522,109110,DB00936,Salicylic acid
,24312851,AUC0-8hr,"Median (% of interquartile range/median) of salicylic acid AUC0-8hr (ng/mL/hr) values in Transcutol(®) or eucalyptus oil treated rats were 2522(139%) and 58976(141%), respectively as compared to the 3023(327%) of the control group.",Percutaneous absorption of salicylic Acid after administration of trolamine salicylate cream in rats with transcutol(®) and eucalyptus oil pre-treated skin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24312851/),[ng] / [h·ml],58976,109111,DB00936,Salicylic acid
,24312851,AUC0-8hr,"Median (% of interquartile range/median) of salicylic acid AUC0-8hr (ng/mL/hr) values in Transcutol(®) or eucalyptus oil treated rats were 2522(139%) and 58976(141%), respectively as compared to the 3023(327%) of the control group.",Percutaneous absorption of salicylic Acid after administration of trolamine salicylate cream in rats with transcutol(®) and eucalyptus oil pre-treated skin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24312851/),[ng] / [h·ml],3023,109112,DB00936,Salicylic acid
,2274970,terminal half-life,The concentration of TOCP in plasma was at maximum by 6 h then declined biexponentially with terminal half-life of 46 h.,"Absorption, distribution, excretion and metabolism of a single oral dose of [14C]tri-o-cresyl phosphate (TOCP) in the male rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2274970/),h,46,113809,DB00936,Salicylic acid
,7226711,Peak plasma salicylate levels,Peak plasma salicylate levels were reached 0.5 to 3 hr after ingestion and averaged 40.1 +/- 17.3 micrograms/ml.,Salicylate absorption from a bismuth subsalicylate preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7226711/),[μg] / [ml],40.1,115318,DB00936,Salicylic acid
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,3.1,118203,DB00936,Salicylic acid
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,4.1,118204,DB00936,Salicylic acid
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,14.8,118205,DB00936,Salicylic acid
,2600795,retention times,"The retention times of 3, 2, 1, and the internal standard chlorpropamide were 3.1, 4.1, 14.8, and 10.0 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,10.0,118206,DB00936,Salicylic acid
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,4.6,118207,DB00936,Salicylic acid
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,6.7,118208,DB00936,Salicylic acid
,2600795,retention times,"Under these conditions, the retention times of the carboxy and hydroxylated metabolites and the internal standard salicylic acid were 4.6, 6.7, and 8.1 min, respectively.",Simultaneous determinations of tolbutamide and its hydroxy and carboxy metabolites in serum and urine: application to pharmacokinetic studies of tolbutamide in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600795/),min,8.1,118209,DB00936,Salicylic acid
,14671681,relative bioavailability,"Furthermore, a relative bioavailability of approximately 100% of the preliminary formulation was shown for the newly developed formulation for all parameters.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),%,100,122142,DB00936,Salicylic acid
,14671681,AUC,"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [h·l],1040.66,122143,DB00936,Salicylic acid
,14671681,AUC,"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [h·l],142.28,122144,DB00936,Salicylic acid
,14671681,C(max),"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [l],134.52,122145,DB00936,Salicylic acid
,14671681,C(max),"For the newly developed formulation, the arithmetic means of the parameters AUC and C(max) for PSE were 1040.66 mg/h*l and 134.52 mg/l, for SA 142.28 mg/h*l and 30.34 mg/l, respectively.",Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),[mg] / [l],30.34,122146,DB00936,Salicylic acid
,14671681,t(max),The median t(max) values were 0.67 h for PSE and 0.92 h for SA.,Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),h,0.67,122147,DB00936,Salicylic acid
,14671681,t(max),The median t(max) values were 0.67 h for PSE and 0.92 h for SA.,Relative bioavailability and bioequivalence of a newly developed fixed combination sachet of acetylsalicylic acid and pseudoephedrine compared with a preliminary combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14671681/),h,0.92,122148,DB00936,Salicylic acid
,11725967,area under the curve (AUC),"Insulin suppositories containing sodium salicylate (50 mg) produced a maximum reduction of plasma glucose concentration (Cmax) of 55 +/- 11%, an area under the curve (AUC) of 252 +/- 59% reduction h; and a relative hypoglycemia (RH) of 49 +/- 12% relative to subcutaneous injection of insulin (4 U/kg).",Relative hypoglycemic effect of insulin suppositories in diabetic beagle dogs: optimization of various concentrations of sodium salicylate and polyoxyethylene-9-lauryl ether. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11725967/),%·h·reduction,252,124708,DB00936,Salicylic acid
,11725967,AUC,"Investigation of the influence of insulin suppositories containing different concentrations of the nonionic surfactant POELE (1, 3, 4%) showed that; the suppositories containing the lowest concentration (1%) produced the highest hypoglycemic effect with a Cmax of 68%, AUC of 332 +/- 67% reduction h, and RH of 55 +/- 11%.",Relative hypoglycemic effect of insulin suppositories in diabetic beagle dogs: optimization of various concentrations of sodium salicylate and polyoxyethylene-9-lauryl ether. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11725967/),%,332,124709,DB00936,Salicylic acid
,11405070,peak values,"The salicylic acid concentrations demonstrated peak values in the residual vitreous (640.0 micrograms/ml), choroid (446.0 ng/mg) and retina (281.3 ng/mg) at 6 h.",Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11405070/),[μg] / [ml],640.0,127345,DB00936,Salicylic acid
,11405070,peak values,"The salicylic acid concentrations demonstrated peak values in the residual vitreous (640.0 micrograms/ml), choroid (446.0 ng/mg) and retina (281.3 ng/mg) at 6 h.",Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11405070/),[ng] / [mg],446.0,127346,DB00936,Salicylic acid
,11405070,peak values,"The salicylic acid concentrations demonstrated peak values in the residual vitreous (640.0 micrograms/ml), choroid (446.0 ng/mg) and retina (281.3 ng/mg) at 6 h.",Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11405070/),[ng] / [mg],281.3,127347,DB00936,Salicylic acid
,1051,half-life,Intravenous injection of 14C-benorylate to rats showed that the drug had a relatively high elimination rate from the blood with a half-life of 1.9 h.,The distribution and elimination of radioactivity in the rat after administration of 14C-4-acetamidophenyl-2-acetoxybenzoate (benorylate). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1051/),h,1.9,129716,DB00936,Salicylic acid
,3802700,GRT,The mean (+/- SD) GRT was significantly delayed by food (0.8 +/- 0.5 vs. 5.9 +/- 3.3 hours; P less than 0.005).,Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802700/),h,0.8,129962,DB00936,Salicylic acid
,3802700,GRT,The mean (+/- SD) GRT was significantly delayed by food (0.8 +/- 0.5 vs. 5.9 +/- 3.3 hours; P less than 0.005).,Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802700/),h,5.9,129963,DB00936,Salicylic acid
,3802700,lag time (TL),The mean (+/- SD) lag time (TL) and time to peak concentration (expressed as salicylic acid equivalents) were markedly prolonged after the fed regimen (2.7 +/- 0.8 vs.,Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802700/),,2.7,129964,DB00936,Salicylic acid
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],1,132975,DB00936,Salicylic acid
,17849506,limits of detection,"The limits of detection of dipyridamole and salicylic acid were 1 and 15 ng/mL, respectively.",Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17849506/),[ng] / [ml],15,132976,DB00936,Salicylic acid
,28556061,TXB2,Baseline TXB2 levels were median 0·35 ng/mL (0·07-0·94).,Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28556061/),[ng] / [ml],0·35,135682,DB00936,Salicylic acid
,19262071,area under the,"However, pharmacokinetic parameters for SA differed significantly: the mean area under the pharmacokinetic curve for the UGT1A6*1 and UGT1A6*2 homozygotes was 136 and 94 microg/ml.h (p = 0.04), and median C(max) was 23 and 17 microg/ml (p = 0.01), respectively.",Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262071/),[μg] / [h·ml],136,136582,DB00936,Salicylic acid
,19262071,area under the,"However, pharmacokinetic parameters for SA differed significantly: the mean area under the pharmacokinetic curve for the UGT1A6*1 and UGT1A6*2 homozygotes was 136 and 94 microg/ml.h (p = 0.04), and median C(max) was 23 and 17 microg/ml (p = 0.01), respectively.",Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262071/),[μg] / [h·ml],94,136583,DB00936,Salicylic acid
,19262071,C(max),"However, pharmacokinetic parameters for SA differed significantly: the mean area under the pharmacokinetic curve for the UGT1A6*1 and UGT1A6*2 homozygotes was 136 and 94 microg/ml.h (p = 0.04), and median C(max) was 23 and 17 microg/ml (p = 0.01), respectively.",Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262071/),[μg] / [ml],23,136584,DB00936,Salicylic acid
,19262071,C(max),"However, pharmacokinetic parameters for SA differed significantly: the mean area under the pharmacokinetic curve for the UGT1A6*1 and UGT1A6*2 homozygotes was 136 and 94 microg/ml.h (p = 0.04), and median C(max) was 23 and 17 microg/ml (p = 0.01), respectively.",Effect of genetic polymorphisms in UDP-glucuronosyltransferase 1A6 (UGT1A6) on acetylsalicylic acid metabolism in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262071/),[μg] / [ml],17,136585,DB00936,Salicylic acid
,21261677,DA/PA ratio,"Mean DA/PA ratio after oral administration of diclofenac to the mother was estimated to be 39.0%, whereas both of the corresponding values after oral administration of antipyrine and salicylic acid were estimated to be 5.9%.",Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21261677/),%,39.0,138449,DB00936,Salicylic acid
,21261677,DA/PA ratio,"Mean DA/PA ratio after oral administration of diclofenac to the mother was estimated to be 39.0%, whereas both of the corresponding values after oral administration of antipyrine and salicylic acid were estimated to be 5.9%.",Prediction and evaluation of fetal toxicity induced by NSAIDs using transplacental kinetic parameters obtained from human placental perfusion studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21261677/),%,5.9,138450,DB00936,Salicylic acid
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],8.88,139795,DB00936,Salicylic acid
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],42.6,139796,DB00936,Salicylic acid
,21091728,peak (C(max) ),"After oral administration of carbasalate calcium, the plasma drug concentration for ASA, SA and GA reached a peak (C(max) ) of 8.88 ± 1.31, 42.6 ± 4.62 and 10.1 ± 2.16 μg/mL at 0.170, 2.00 and 2.00 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),[μg] / [ml],10.1,139797,DB00936,Salicylic acid
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,11.2,139798,DB00936,Salicylic acid
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,23.7,139799,DB00936,Salicylic acid
,21091728,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) of ASA, SA and GA was 11.2 ± 8.04, 23.7 ± 17.1 and 28.6 ± 4.90 h, respectively.",Analytical determination and pharmacokinetics of major metabolites of carbasalate calcium in broilers following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21091728/),h,28.6,139800,DB00936,Salicylic acid
,17763375,t(1/2),Atenolol aspirinate was stable towards aqueous hydrolysis but rapidly hydrolyzed in plasma (t(1/2) = 7.6 min).,Pharmacokinetic profile of atenolol aspirinate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17763375/),min,7.6,140392,DB00936,Salicylic acid
<,10701434,run times,"The method has a lower limit of quantification (LLOQ) adequate for sensitive pharmacokinetic studies ( < or = 0.05 microg/ml), has run times of < or = 15 min, and uses aliquot volumes adequate for pediatric studies (0.25 ml).","A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),min,15,140499,DB00936,Salicylic acid
,10701434,lambda(ex),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,278,140500,DB00936,Salicylic acid
,10701434,lambda(em),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,380,140501,DB00936,Salicylic acid
<,10701434,% C.V.,All intra- and inter-assay % C.V. values were < 8%; all recoveries (accuracy) were within 7% of nominal values.,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),%,8,140502,DB00936,Salicylic acid
,6859071,accumulation,"After intraperitoneal administration, salicylate levels in rabbit plasma, similar to those of humans receiving four to six aspirin tablets (325 mg each), result in accumulation of salicylate by lens (mean +/- SD) of 405 +/- 72 mumoles/g and 620 +/- 30 mumoles/g at two and four hours, respectively.",Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859071/),[mumoles] / [g],405,140922,DB00936,Salicylic acid
,6859071,accumulation,"After intraperitoneal administration, salicylate levels in rabbit plasma, similar to those of humans receiving four to six aspirin tablets (325 mg each), result in accumulation of salicylate by lens (mean +/- SD) of 405 +/- 72 mumoles/g and 620 +/- 30 mumoles/g at two and four hours, respectively.",Distribution of salicylate in lens and intraocular fluids and its effect on cataract formation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6859071/),[mumoles] / [g],620,140923,DB00936,Salicylic acid
,7965801,clearance,"In healthy and FIC cats, the clearance was 0.3 and 0.1 ml.min-1.kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively.",Effect of interstitial cystitis on drug absorption from urinary bladder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965801/),[ml] / [kg·min],0.3,143830,DB00936,Salicylic acid
,7965801,clearance,"In healthy and FIC cats, the clearance was 0.3 and 0.1 ml.min-1.kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively.",Effect of interstitial cystitis on drug absorption from urinary bladder. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965801/),[ml] / [kg·min],0.1,143831,DB00936,Salicylic acid
,7965801,bioavailability,"In healthy and FIC cats, the clearance was 0.3 and 0.1 ml.min-1.kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively.",Effect of interstitial cystitis on drug absorption from urinary bladder. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965801/),%,1,143832,DB00936,Salicylic acid
,7965801,bioavailability,"In healthy and FIC cats, the clearance was 0.3 and 0.1 ml.min-1.kg-1, and the bioavailability of the intravesical dose was about 1 and 9%, respectively.",Effect of interstitial cystitis on drug absorption from urinary bladder. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965801/),%,9,143833,DB00936,Salicylic acid
,33990657,Vmax,"Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),,6.5,145779,DB00936,Salicylic acid
,33990657,Km,"Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),,147.5,145780,DB00936,Salicylic acid
,33990657,Vmax,"Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),,108.1,145781,DB00936,Salicylic acid
,33990657,Km,"Parameters of esterases activity were Vmax 6.5 ± 1.9 and Km 147.5 ± 64.4 in plasma, and Vmax 108.1 ± 20.8 and Km 803.2 ± 170.7 in whole blood.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),,803.2,145782,DB00936,Salicylic acid
,33990657,tmax,"After oral administration of the two formulations, tmax varied between 3 and 6 h for EC-ASA and between 0.5 and 1.0 h for plain-ASA.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),h,3 and 6,145783,DB00936,Salicylic acid
,33990657,tmax,"After oral administration of the two formulations, tmax varied between 3 and 6 h for EC-ASA and between 0.5 and 1.0 h for plain-ASA.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),h,0.5 and 1.0,145784,DB00936,Salicylic acid
,33990657,Plasma AUC,"Plasma AUC was 725.5 (89.8-1222) for EC-ASA, and 823.1(624-1196) ng h/mL (median, 25-75% CI) for plain ASA.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),[h·ng] / [ml],725.5,145785,DB00936,Salicylic acid
,33990657,Plasma AUC,"Plasma AUC was 725.5 (89.8-1222) for EC-ASA, and 823.1(624-1196) ng h/mL (median, 25-75% CI) for plain ASA.",In-vitro and in-vivo metabolism of different aspirin formulations studied by a validated liquid chromatography tandem mass spectrometry method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33990657/),[h·ng] / [ml],823.1,145786,DB00936,Salicylic acid
,10541883,SA concentrations,"Microdialysates collected between 80 and 200 min showed mean SA concentrations of 3 microg/ml in unmodified and acetone-treated skin, whereas mean SA concentrations were 280 microg/ml in SLS-pretreated skin and 530 microg/ml in tape-stripped skin (P < 0.001).",Effect of barrier perturbation on cutaneous penetration of salicylic acid in hairless rats: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10541883/),[μg] / [ml],3,151017,DB00936,Salicylic acid
,10541883,SA concentrations,"Microdialysates collected between 80 and 200 min showed mean SA concentrations of 3 microg/ml in unmodified and acetone-treated skin, whereas mean SA concentrations were 280 microg/ml in SLS-pretreated skin and 530 microg/ml in tape-stripped skin (P < 0.001).",Effect of barrier perturbation on cutaneous penetration of salicylic acid in hairless rats: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10541883/),[μg] / [ml],280,151018,DB00936,Salicylic acid
,10541883,SA concentrations,"Microdialysates collected between 80 and 200 min showed mean SA concentrations of 3 microg/ml in unmodified and acetone-treated skin, whereas mean SA concentrations were 280 microg/ml in SLS-pretreated skin and 530 microg/ml in tape-stripped skin (P < 0.001).",Effect of barrier perturbation on cutaneous penetration of salicylic acid in hairless rats: in vivo pharmacokinetics using microdialysis and non-invasive quantification of barrier function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10541883/),[μg] / [ml],530,151019,DB00936,Salicylic acid
,4024217,Minimum concentrations,Minimum concentrations of 10 micrograms/L (aspirin) and 0.5 mg/L (salicylate) can be measured using 1 ml of plasma.,A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024217/),[μg] / [l],10,152142,DB00936,Salicylic acid
,4024217,Minimum concentrations,Minimum concentrations of 10 micrograms/L (aspirin) and 0.5 mg/L (salicylate) can be measured using 1 ml of plasma.,A sensitive liquid chromatographic assay for plasma aspirin and salicylate concentrations after low doses of aspirin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024217/),[mg] / [l],0.5,152143,DB00936,Salicylic acid
,34303214,flow rate,"The mobile phase consists of acetonitrile and 0.5 mM ammonium acetate in water, and these compounds were well separated at a gradient elution program with flow rate of 0.35 mL/min.",Simultaneous determination of twenty-five compounds with anti-inflammatory activity in Spatholobi Caulis by using an optimized UFLC-MS/MS method: An application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34303214/),[ml] / [min],0.35,152424,DB00936,Salicylic acid
,34303214,IC50,"Isoflavones, especially compounds 20-22 (The IC50 of which were 22.75 μM, 21.11 μM and 48.29 μM, respectively.) might be the important constituents for anti-inflammatory activity of SPC.",Simultaneous determination of twenty-five compounds with anti-inflammatory activity in Spatholobi Caulis by using an optimized UFLC-MS/MS method: An application to pharmacokinetic study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34303214/),μM,22.75,152425,DB00936,Salicylic acid
,34303214,IC50,"Isoflavones, especially compounds 20-22 (The IC50 of which were 22.75 μM, 21.11 μM and 48.29 μM, respectively.) might be the important constituents for anti-inflammatory activity of SPC.",Simultaneous determination of twenty-five compounds with anti-inflammatory activity in Spatholobi Caulis by using an optimized UFLC-MS/MS method: An application to pharmacokinetic study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34303214/),μM,21.11,152426,DB00936,Salicylic acid
,34303214,IC50,"Isoflavones, especially compounds 20-22 (The IC50 of which were 22.75 μM, 21.11 μM and 48.29 μM, respectively.) might be the important constituents for anti-inflammatory activity of SPC.",Simultaneous determination of twenty-five compounds with anti-inflammatory activity in Spatholobi Caulis by using an optimized UFLC-MS/MS method: An application to pharmacokinetic study. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34303214/),μM,48.29,152427,DB00936,Salicylic acid
,2238859,constant plasma levels,By use of bathing concentration of 0.33 g/l of salicylic acid constant plasma levels of 10 +/- 1.27 ng/ml were found in a period of 24 h.,[Pharmacokinetic study of percutaneous absorption of salicylic acid from baths with salicylate methyl ester and salicylic acid]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2238859/),[ng] / [ml],10,154369,DB00936,Salicylic acid
,2238859,renal elimination,"The renal elimination of 0.92 +/- 0.14 at first day, 0.72 +/- 0.11 at second day, and 0.50 +/- 0.08 mg salicyluric acid at third day was found.",[Pharmacokinetic study of percutaneous absorption of salicylic acid from baths with salicylate methyl ester and salicylic acid]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2238859/),mg,0.92,154370,DB00936,Salicylic acid
,2238859,renal elimination,"The renal elimination of 0.92 +/- 0.14 at first day, 0.72 +/- 0.11 at second day, and 0.50 +/- 0.08 mg salicyluric acid at third day was found.",[Pharmacokinetic study of percutaneous absorption of salicylic acid from baths with salicylate methyl ester and salicylic acid]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2238859/),mg,0.72,154371,DB00936,Salicylic acid
,2238859,renal elimination,"The renal elimination of 0.92 +/- 0.14 at first day, 0.72 +/- 0.11 at second day, and 0.50 +/- 0.08 mg salicyluric acid at third day was found.",[Pharmacokinetic study of percutaneous absorption of salicylic acid from baths with salicylate methyl ester and salicylic acid]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2238859/),mg,0.50,154372,DB00936,Salicylic acid
,2238859,half-time of elimination,The half-time of elimination in urine after methyl salicylate bathing is (as with injected salicylic acid) between 2.4 to 4 h.,[Pharmacokinetic study of percutaneous absorption of salicylic acid from baths with salicylate methyl ester and salicylic acid]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2238859/),h,2.4 to 4,154373,DB00936,Salicylic acid
,2238859,half-time of elimination,"Conversely half-time of elimination in urine by salicylic acid bathing is between 30 to 50 h, and is greater with salicylic acid bathing than with other application forms.",[Pharmacokinetic study of percutaneous absorption of salicylic acid from baths with salicylate methyl ester and salicylic acid]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2238859/),h,30 to 50,154374,DB00936,Salicylic acid
,6435136,time up to the maximum serum concentration,"The absorption kinetics of the preparations were different: the time up to the maximum serum concentration was at Turivital with 1,3 +/- 0,7 h and Micristin (2,1 +/- 0,8 h) the shortest, because the resorption delay was at Turivital the smallest.","[Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435136/),h,"1,3",155977,DB00936,Salicylic acid
,6435136,time up to the maximum serum concentration,"The absorption kinetics of the preparations were different: the time up to the maximum serum concentration was at Turivital with 1,3 +/- 0,7 h and Micristin (2,1 +/- 0,8 h) the shortest, because the resorption delay was at Turivital the smallest.","[Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435136/),h,"2,1",155978,DB00936,Salicylic acid
,3378803,maximal plasma levels,Two cases of severe salicylate poisoning with maximal plasma levels of 6.9 and 8.9 mmol/l are described.,Haemodialysis or haemoperfusion in severe salicylate poisoning? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[mM] / [l],6.9,158689,DB00936,Salicylic acid
,3378803,maximal plasma levels,Two cases of severe salicylate poisoning with maximal plasma levels of 6.9 and 8.9 mmol/l are described.,Haemodialysis or haemoperfusion in severe salicylate poisoning? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[mM] / [l],8.9,158690,DB00936,Salicylic acid
,3378803,dial,"There was a non-significant higher dialysance (mean 86 ml/min, s.d. +/- 8) than haemoperfusion clearance (mean 81 ml/min s.d. +/- 17) at a blood flow of 200 ml/min.",Haemodialysis or haemoperfusion in severe salicylate poisoning? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[ml] / [min],86,158691,DB00936,Salicylic acid
,3378803,clearance,"There was a non-significant higher dialysance (mean 86 ml/min, s.d. +/- 8) than haemoperfusion clearance (mean 81 ml/min s.d. +/- 17) at a blood flow of 200 ml/min.",Haemodialysis or haemoperfusion in severe salicylate poisoning? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[ml] / [min],81,158692,DB00936,Salicylic acid
,3378803,blood flow,"There was a non-significant higher dialysance (mean 86 ml/min, s.d. +/- 8) than haemoperfusion clearance (mean 81 ml/min s.d. +/- 17) at a blood flow of 200 ml/min.",Haemodialysis or haemoperfusion in severe salicylate poisoning? ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378803/),[ml] / [min],200,158693,DB00936,Salicylic acid
,25998572,half-life,"ASA acetylates cyclooxygenase in the portal circulation and is rapidly (half-life, 20 min) hydrolyzed.",A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25998572/),min,20,158883,DB00936,Salicylic acid
,10537230,bioavailability,"With a single administration of 300 mg/kg of the extract, aspirin blood levels were undetectable while salicylic acid bioavailability was reduced in 59%.",Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537230/),%,59,159422,DB00936,Salicylic acid
,10537230,bioavailability,"Chronic administration once daily for 4 weeks of 100 and 300 mg/kg of the extract resulted in undetectable aspirin blood levels, while salicylic acid bioavailability was reduced in 63 and 76%, respectively, compared with controls.",Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537230/),%,63,159423,DB00936,Salicylic acid
,10537230,bioavailability,"Chronic administration once daily for 4 weeks of 100 and 300 mg/kg of the extract resulted in undetectable aspirin blood levels, while salicylic acid bioavailability was reduced in 63 and 76%, respectively, compared with controls.",Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10537230/),%,76,159424,DB00936,Salicylic acid
,6500763,Plasma protein binding,Plasma protein binding of isofezolac was very high (99%) and did not influence salicylic acid binding.,The effect of antacid and aspirin on the bioavailability of isofezolac in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500763/),%,99,159966,DB00936,Salicylic acid
,23798357,flow rate,"The mobile phase consisted of aqueous solution containing 0.1% phosphoric acid and acetonitrile (82:90, v/v), at a flow rate of 1 mL/min.","Pharmacokinetics of methyl salicylate-2-O-β-D-lactoside, a novel salicylic acid analog isolated from Gaultheria yunnanensis, in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23798357/),[ml] / [min],1,164417,DB00936,Salicylic acid
,22465277,area under the concentration time curve (AUC),"The pharmacokinetic data demonstrate that the area under the concentration time curve (AUC) of the aspirin was 2031 ± 266 min μg/mL after aspirin administration (100mg/kg, i.v.).",Simultaneous determination and pharmacokinetics of protein unbound aspirin and salicylic acid in rat blood and brain by microdialysis: an application to herbal-drug interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465277/),[min·μg] / [ml],2031,165126,DB00936,Salicylic acid
,22465277,AUC,"The AUC of salicylic acid was 12660 ± 1799 min μg/mL, which suggests that aspirin is quickly hydrolyzed to salicylic acid in blood and the metabolite can also be detected within 15 min in brain dialysate.",Simultaneous determination and pharmacokinetics of protein unbound aspirin and salicylic acid in rat blood and brain by microdialysis: an application to herbal-drug interaction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465277/),[min·μg] / [ml],12660,165127,DB00936,Salicylic acid
,7094976,time until 50%,"The median time until 50% and 90% were emptied from the stomach was 1 and 3-3.5 h, respectively, for both the uncoated and enteric-coated granules.",Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated micro-granules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094976/),h,1,165412,DB00936,Salicylic acid
,7094976,time until 50%,"The median time until 50% and 90% were emptied from the stomach was 1 and 3-3.5 h, respectively, for both the uncoated and enteric-coated granules.",Gastric emptying and absorption of acetylsalicylic acid administered as enteric-coated micro-granules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094976/),h,3-3.5,165413,DB00936,Salicylic acid
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.28,166074,DB00936,Salicylic acid
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,66.99,166075,DB00936,Salicylic acid
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.22,166076,DB00936,Salicylic acid
,11850685,AUCs (the,"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,69.48,166077,DB00936,Salicylic acid
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.28,166078,DB00936,Salicylic acid
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,66.99,166079,DB00936,Salicylic acid
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,3.22,166080,DB00936,Salicylic acid
,11850685,area under the plasma concentration versus time curve from time zero to time infinity),"ASA and SA AUCs (the area under the plasma concentration versus time curve from time zero to time infinity) respectively were 3.28 plus minus 0.80 and 66.99 plus minus 11.73 &mgr;g h ml(minus sign1) (ASA alone), and 3.22 plus minus 0.61 and 69.48 plus minus 15.79 &mgr;g h ml(minus sign1) (ASA with warfarin).",Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,69.48,166081,DB00936,Salicylic acid
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),,33.9,166082,DB00936,Salicylic acid
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),,23.9,166083,DB00936,Salicylic acid
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,33.6,166084,DB00936,Salicylic acid
,11850685,AUCs,R-warfarin and S-warfarin AUCs respectively were 33.9 plus minus 9.3 and 23.9 plus minus 16.0 &mgr;g h ml(minus sign1) (warfarin alone) and 33.6 plus minus 10.2 and 22.6 plus minus 14.7 &mgr;g h ml(minus sign1) (warfarin with ASA).,Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850685/),g·h·ml,22.6,166085,DB00936,Salicylic acid
,2758104,area under curve,"Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate).",Pharmacokinetic interactions between arbaprostil and aspirin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758104/),[μg] / [hml],5.09,177623,DB00936,Salicylic acid
,2758104,area under curve,"Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate).",Pharmacokinetic interactions between arbaprostil and aspirin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758104/),[μg] / [hml],5.78,177624,DB00936,Salicylic acid
,2758104,time,"Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate).",Pharmacokinetic interactions between arbaprostil and aspirin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758104/),h,0.45,177625,DB00936,Salicylic acid
,2758104,time,"Coadministration of arbaprostil significantly lowered the area under curve (5.09 +/- 0.32 micrograms hml-1 vs 5.78 +/- 0.29 micrograms hml-1, mean +/- SE, p less than 0.05) and time (0.45 +/- 0.07 h vs 0.70 +/- 0.12 h, p less than 0.05) to reach maximal plasma concentration of aspirin (acetylsalicylate).",Pharmacokinetic interactions between arbaprostil and aspirin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2758104/),h,0.70,177626,DB00936,Salicylic acid
,7486364,peak salicylate concentrations,"The mean peak salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = .74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.",Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486364/),[mg] / [dl],47.4,178070,DB00936,Salicylic acid
,7486364,peak salicylate concentrations,"The mean peak salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = .74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.",Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486364/),[mg] / [dl],48.4,178071,DB00936,Salicylic acid
,7486364,areas under the time-serum salicylate concentration curve over 6 hours,"The mean peak salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = .74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.",Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486364/),[mg·min] / [l],"171,000",178072,DB00936,Salicylic acid
,7486364,areas under the time-serum salicylate concentration curve over 6 hours,"The mean peak salicylate concentrations were 47.4 +/- 6.2 mg/dL and 48.4 +/- 3.9 mg/dL (P = .74), and the areas under the time-serum salicylate concentration curve over 6 hours were 171,000 +/- 24,000 mg.minute/L and 188,000 +/- 18,000 mg.",Effect of multiple-dose activated charcoal on the clearance of high-dose intravenous aspirin in a porcine model. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486364/),mg,"188,000",178073,DB00936,Salicylic acid
,2510140,clearance,"After intravenous injection mean (+/- SD) values of clearance, steady-state volume of distribution, and terminal half-life were 12.2 +/- 2.2 ml/min/kg, 0.219 +/- 0.042 liter/kg, and 15.4 +/- 2.5 min, respectively, with no differences between males and females.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),[ml] / [kg·min],12.2,182118,DB00936,Salicylic acid
,2510140,steady-state volume of distribution,"After intravenous injection mean (+/- SD) values of clearance, steady-state volume of distribution, and terminal half-life were 12.2 +/- 2.2 ml/min/kg, 0.219 +/- 0.042 liter/kg, and 15.4 +/- 2.5 min, respectively, with no differences between males and females.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),[l] / [kg],0.219,182119,DB00936,Salicylic acid
,2510140,terminal half-life,"After intravenous injection mean (+/- SD) values of clearance, steady-state volume of distribution, and terminal half-life were 12.2 +/- 2.2 ml/min/kg, 0.219 +/- 0.042 liter/kg, and 15.4 +/- 2.5 min, respectively, with no differences between males and females.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,15.4,182120,DB00936,Salicylic acid
,2510140,mean absorption times,"Following administration aspirin was absorbed more quickly in females than in males (mean absorption times of 16.4 and 21.3 min, respectively although the bioavailability, 54%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,16.4,182121,DB00936,Salicylic acid
,2510140,mean absorption times,"Following administration aspirin was absorbed more quickly in females than in males (mean absorption times of 16.4 and 21.3 min, respectively although the bioavailability, 54%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,21.3,182122,DB00936,Salicylic acid
,2510140,bioavailability,"Following administration aspirin was absorbed more quickly in females than in males (mean absorption times of 16.4 and 21.3 min, respectively although the bioavailability, 54%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),%,54,182123,DB00936,Salicylic acid
,2510140,mean absorption time,"In contrast, following intramuscular administration, aspirin was absorbed more slowly in females than males (mean absorption time of 97 and 53 min, respectively) but again the bioavailability, 89%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,97,182124,DB00936,Salicylic acid
,2510140,mean absorption time,"In contrast, following intramuscular administration, aspirin was absorbed more slowly in females than males (mean absorption time of 97 and 53 min, respectively) but again the bioavailability, 89%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),min,53,182125,DB00936,Salicylic acid
,2510140,bioavailability,"In contrast, following intramuscular administration, aspirin was absorbed more slowly in females than males (mean absorption time of 97 and 53 min, respectively) but again the bioavailability, 89%, was the same in both groups.","Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2510140/),%,89,182126,DB00936,Salicylic acid
,6148219,volume of distribution,"In the pregnant rats, the volume of distribution increased significantly (p less than 0.05) from 164 ml/kg of the control to 225 ml/kg, and the total body clearance also increased significantly (p less than 0.05) from 12.1 ml/hr/kg of the control to 19.8 ml/hr/kg.",Effect of pregnancy on tissue distribution of salicylate in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148219/),[ml] / [kg],164,184451,DB00936,Salicylic acid
,6148219,volume of distribution,"In the pregnant rats, the volume of distribution increased significantly (p less than 0.05) from 164 ml/kg of the control to 225 ml/kg, and the total body clearance also increased significantly (p less than 0.05) from 12.1 ml/hr/kg of the control to 19.8 ml/hr/kg.",Effect of pregnancy on tissue distribution of salicylate in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148219/),[ml] / [kg],225,184452,DB00936,Salicylic acid
,6148219,total body clearance,"In the pregnant rats, the volume of distribution increased significantly (p less than 0.05) from 164 ml/kg of the control to 225 ml/kg, and the total body clearance also increased significantly (p less than 0.05) from 12.1 ml/hr/kg of the control to 19.8 ml/hr/kg.",Effect of pregnancy on tissue distribution of salicylate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148219/),[ml] / [h·kg],12.1,184453,DB00936,Salicylic acid
,6148219,total body clearance,"In the pregnant rats, the volume of distribution increased significantly (p less than 0.05) from 164 ml/kg of the control to 225 ml/kg, and the total body clearance also increased significantly (p less than 0.05) from 12.1 ml/hr/kg of the control to 19.8 ml/hr/kg.",Effect of pregnancy on tissue distribution of salicylate in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148219/),[ml] / [h·kg],19.8,184454,DB00936,Salicylic acid
,6148219,serum unbound fraction (fs),The serum unbound fraction (fs) of the pregnant rats at 8 hr after iv administration of salicylate increased remarkably from 0.14 of the control to 0.67.,Effect of pregnancy on tissue distribution of salicylate in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148219/),,0.14,184455,DB00936,Salicylic acid
,6148219,serum unbound fraction (fs),The serum unbound fraction (fs) of the pregnant rats at 8 hr after iv administration of salicylate increased remarkably from 0.14 of the control to 0.67.,Effect of pregnancy on tissue distribution of salicylate in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148219/),,0.67,184456,DB00936,Salicylic acid
,6148219,fs,The fs in the fetal serum (0.41) was lower than that in the maternal serum in spite of the lower albumin concentration in the fetal serum.,Effect of pregnancy on tissue distribution of salicylate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148219/),,0.41,184457,DB00936,Salicylic acid
,17523057,Total recovery,Total recovery of the administered dose was on average 89% for male dogs and 95% for female dogs.,"Metabolism and excretion of CP-122,721, a non-peptide antagonist of the neurokinin NK1 receptor, in dogs: identification of the novel cleaved product 5-trifluoromethoxy salicylic acid in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523057/),%,89,184850,DB00936,Salicylic acid
,17523057,Total recovery,Total recovery of the administered dose was on average 89% for male dogs and 95% for female dogs.,"Metabolism and excretion of CP-122,721, a non-peptide antagonist of the neurokinin NK1 receptor, in dogs: identification of the novel cleaved product 5-trifluoromethoxy salicylic acid in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17523057/),%,95,184851,DB00936,Salicylic acid
,12485350,half-life,"After intravenous administration of sodium salicylate (50 mg/kg), FLU (1.1 mg/kg) and MEL (0.5 mg/kg), these drugs were eliminated from plasma with a mean half-life of 04.04, 05.45 and 03.20 h, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),h,04.04,186503,DB00936,Salicylic acid
,12485350,half-life,"After intravenous administration of sodium salicylate (50 mg/kg), FLU (1.1 mg/kg) and MEL (0.5 mg/kg), these drugs were eliminated from plasma with a mean half-life of 04.04, 05.45 and 03.20 h, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),h,05.45,186504,DB00936,Salicylic acid
,12485350,half-life,"After intravenous administration of sodium salicylate (50 mg/kg), FLU (1.1 mg/kg) and MEL (0.5 mg/kg), these drugs were eliminated from plasma with a mean half-life of 04.04, 05.45 and 03.20 h, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),h,03.20,186505,DB00936,Salicylic acid
,12485350,Apparent volumes of distribution,"Apparent volumes of distribution (0.39, 0.08 and 0.12 L/kg, respectively) indicated that tissue distribution was limited for the three drugs.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[l] / [kg],0.39,186506,DB00936,Salicylic acid
,12485350,Apparent volumes of distribution,"Apparent volumes of distribution (0.39, 0.08 and 0.12 L/kg, respectively) indicated that tissue distribution was limited for the three drugs.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[l] / [kg],0.08,186507,DB00936,Salicylic acid
,12485350,Apparent volumes of distribution,"Apparent volumes of distribution (0.39, 0.08 and 0.12 L/kg, respectively) indicated that tissue distribution was limited for the three drugs.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[l] / [kg],0.12,186508,DB00936,Salicylic acid
,12485350,Total body clearance,"Total body clearance was 70 mL/h.kg for sodium salicylate and 10 and 25 mL/kg.h for FLU and MEL, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[ml] / [h·kg],70,186509,DB00936,Salicylic acid
,12485350,Total body clearance,"Total body clearance was 70 mL/h.kg for sodium salicylate and 10 and 25 mL/kg.h for FLU and MEL, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[ml] / [h·kg],10,186510,DB00936,Salicylic acid
,12485350,Total body clearance,"Total body clearance was 70 mL/h.kg for sodium salicylate and 10 and 25 mL/kg.h for FLU and MEL, respectively.","Disposition of sodium salicylate, flunixin and meloxicam after intravenous administration in broiler chickens. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485350/),[ml] / [h·kg],25,186511,DB00936,Salicylic acid
,3582479,clearance,"With increasing ASA dosage, mean clearance of SA to SPG was approximately constant (1.8 +/- 0.3, 1.7 +/- 0.2, and 1.5 +/- 0.2 ml/min at 1, 2 and 4 g/day, respectively) when related to plasma concentrations of total SA.",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],1.8,187238,DB00936,Salicylic acid
,3582479,clearance,"With increasing ASA dosage, mean clearance of SA to SPG was approximately constant (1.8 +/- 0.3, 1.7 +/- 0.2, and 1.5 +/- 0.2 ml/min at 1, 2 and 4 g/day, respectively) when related to plasma concentrations of total SA.",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],1.7,187239,DB00936,Salicylic acid
,3582479,clearance,"With increasing ASA dosage, mean clearance of SA to SPG was approximately constant (1.8 +/- 0.3, 1.7 +/- 0.2, and 1.5 +/- 0.2 ml/min at 1, 2 and 4 g/day, respectively) when related to plasma concentrations of total SA.",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],1.5,187240,DB00936,Salicylic acid
,3582479,clearance,"It was concluded, however, that the conversion of SA to SPG is saturable, since the mean clearance of SA to SPG decreased when calculated with respect to the plasma concentration of unbound SA (13.4 +/- 1.6, 11.0 +/- 1.4, and 6.6 +/- 1.9 ml/min at 1, 2 and 4 g/day, respectively).",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],13.4,187241,DB00936,Salicylic acid
,3582479,clearance,"It was concluded, however, that the conversion of SA to SPG is saturable, since the mean clearance of SA to SPG decreased when calculated with respect to the plasma concentration of unbound SA (13.4 +/- 1.6, 11.0 +/- 1.4, and 6.6 +/- 1.9 ml/min at 1, 2 and 4 g/day, respectively).",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],11.0,187242,DB00936,Salicylic acid
,3582479,clearance,"It was concluded, however, that the conversion of SA to SPG is saturable, since the mean clearance of SA to SPG decreased when calculated with respect to the plasma concentration of unbound SA (13.4 +/- 1.6, 11.0 +/- 1.4, and 6.6 +/- 1.9 ml/min at 1, 2 and 4 g/day, respectively).",Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582479/),[ml] / [min],6.6,187243,DB00936,Salicylic acid
,11599656,Peak serum levels,"Peak serum levels of salicylic acid were on average 1.2 mg/l, and the observed area under the serum concentration time curve (AUC) of salicylic acid was equivalent to that expected from an intake of 87 mg acetylsalicylic acid.",Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11599656/),[mg] / [l],1.2,188852,DB00936,Salicylic acid
,9832362,standard curves,The standard curves ranged from 31 ng/ml to 800 or 1250 ng/ml.,"Simultaneous quantitative analysis of methyl salicylate, ethyl salicylate and salicylic acid from biological fluids using gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832362/),[ng] / [ml],31,195178,DB00936,Salicylic acid
,9832362,standard curves,The standard curves ranged from 31 ng/ml to 800 or 1250 ng/ml.,"Simultaneous quantitative analysis of methyl salicylate, ethyl salicylate and salicylic acid from biological fluids using gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832362/),[ng] / [ml],800,195179,DB00936,Salicylic acid
,9832362,standard curves,The standard curves ranged from 31 ng/ml to 800 or 1250 ng/ml.,"Simultaneous quantitative analysis of methyl salicylate, ethyl salicylate and salicylic acid from biological fluids using gas chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9832362/),[ng] / [ml],1250,195180,DB00936,Salicylic acid
,3179172,whole body clearance,Concomitant prednisone therapy did not increase the whole body clearance of single doses of salicylate in these subjects (0.0275 +/- 0.08 l kg-1 h-1 before prednisone; 0.0247 +/- 0.03 l kg-1 h-1 during prednisone therapy; P greater than 0.05).,Interaction of salicylate and corticosteroids in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179172/),[l] / [h·kg],0.0275,196137,DB00936,Salicylic acid
,3179172,whole body clearance,Concomitant prednisone therapy did not increase the whole body clearance of single doses of salicylate in these subjects (0.0275 +/- 0.08 l kg-1 h-1 before prednisone; 0.0247 +/- 0.03 l kg-1 h-1 during prednisone therapy; P greater than 0.05).,Interaction of salicylate and corticosteroids in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179172/),[l] / [h·kg],0.0247,196138,DB00936,Salicylic acid
,1841835,mean residence time in the body (MRT),"Oral aspirin is characterized by its longer mean residence time in the body (MRT), an indicator for duration of exposure, than intravenous aspirin (1.18 vs. 0.37 h).",Disposition of single-dose intravenous and oral aspirin in children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),h,1.18,196546,DB00936,Salicylic acid
,1841835,mean residence time in the body (MRT),"Oral aspirin is characterized by its longer mean residence time in the body (MRT), an indicator for duration of exposure, than intravenous aspirin (1.18 vs. 0.37 h).",Disposition of single-dose intravenous and oral aspirin in children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),h,0.37,196547,DB00936,Salicylic acid
,1841835,apparent elimination half-life (t1/2),The apparent elimination half-life (t1/2) of acetylsalicylic acid was also longer after oral than after intravenous administration of aspirin (40 vs. 17 min).,Disposition of single-dose intravenous and oral aspirin in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),min,40,196548,DB00936,Salicylic acid
,1841835,apparent elimination half-life (t1/2),The apparent elimination half-life (t1/2) of acetylsalicylic acid was also longer after oral than after intravenous administration of aspirin (40 vs. 17 min).,Disposition of single-dose intravenous and oral aspirin in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),min,17,196549,DB00936,Salicylic acid
,1841835,mean absorption time,The mean absorption time was calculated to be as long as 0.8 h.,Disposition of single-dose intravenous and oral aspirin in children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1841835/),h,0.8,196550,DB00936,Salicylic acid
,30021951,elimination half-life (T1/2 el),The elimination half-life (T1/2 el) of SA after IV administration of 200 mg/kg SS was 1.16 ± 0.32 h.,Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30021951/),h,1.16,198648,DB00936,Salicylic acid
,30021951,bioavailability,"Mean bioavailability of SA was 64%, and mean T1/2 el was 1.90 ± 0.35 h, after 200 mg/kg of oral SS.",Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30021951/),%,64,198649,DB00936,Salicylic acid
,30021951,T1/2 el,"Mean bioavailability of SA was 64%, and mean T1/2 el was 1.90 ± 0.35 h, after 200 mg/kg of oral SS.",Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30021951/),h,1.90,198650,DB00936,Salicylic acid
,30021951,minimum plasma SA concentration,The minimum plasma SA concentration (16.8 µg/mL) reported to produce analgesia in humans was achieved after IV administration of 100 and 200 mg/kg SS in sheep for about 0.17 h in this study.,Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30021951/),[μg] / [ml],16.8,198651,DB00936,Salicylic acid
,3252041,steady-state SA serum concentrations,The renal clearance of sulfate and creatinine were examined at mean steady-state SA serum concentrations of 249 micrograms/ml.,Sulfate homeostasis. I. Effect of salicylic acid and its metabolites on inorganic sulfate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252041/),[μg] / [ml],249,201568,DB00936,Salicylic acid
,3252041,renal clearance,"Although no changes in the serum concentrations and renal clearance of creatinine were observed, the renal clearance of inorganic sulfate was increased significantly (2.13 +/- 0.74 vs.",Sulfate homeostasis. I. Effect of salicylic acid and its metabolites on inorganic sulfate in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252041/),,2.13,201569,DB00936,Salicylic acid
,3252041,steady-state concentrations,The effects on sulfate disposition also were probably not due to the major metabolites of SA: no changes in the serum concentrations or renal clearance of sulfate were observed at mean steady-state concentrations of 52 micrograms/ml of salicyluric acid or 73.7 micrograms/ml of salicyl phenolic glucuronide after their direct administration.,Sulfate homeostasis. I. Effect of salicylic acid and its metabolites on inorganic sulfate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252041/),[μg] / [ml],52,201570,DB00936,Salicylic acid
,3252041,steady-state concentrations,The effects on sulfate disposition also were probably not due to the major metabolites of SA: no changes in the serum concentrations or renal clearance of sulfate were observed at mean steady-state concentrations of 52 micrograms/ml of salicyluric acid or 73.7 micrograms/ml of salicyl phenolic glucuronide after their direct administration.,Sulfate homeostasis. I. Effect of salicylic acid and its metabolites on inorganic sulfate in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252041/),[μg] / [ml],73.7,201571,DB00936,Salicylic acid
,3385642,total clearance,"Intravenous injection and oral administration of aspirin (200 mg/kg) showed that the drug is eliminated rapidly (total clearance approximately 45 ml/min/kg; half-life approximately 8 min), that only about one-fourth of the dose is absorbed intact, and that the systemic availability of the oral dose is highly variable (coefficient of variation approximately 60%).",Nonlinear pharmacokinetics of aspirin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385642/),[ml] / [kg·min],45,203026,DB00936,Salicylic acid
,3385642,half-life,"Intravenous injection and oral administration of aspirin (200 mg/kg) showed that the drug is eliminated rapidly (total clearance approximately 45 ml/min/kg; half-life approximately 8 min), that only about one-fourth of the dose is absorbed intact, and that the systemic availability of the oral dose is highly variable (coefficient of variation approximately 60%).",Nonlinear pharmacokinetics of aspirin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385642/),min,8,203027,DB00936,Salicylic acid
,3385642,systemic availability,"The systemic availability of aspirin infused into the portal circulation was about 80% over a wide range of infusion rates, showing that presystemic hydrolysis of the drug occurs mainly in the gut.",Nonlinear pharmacokinetics of aspirin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385642/),%,80,203028,DB00936,Salicylic acid
,2072307,maximal blood concentrations,"The intravesical administration of SA produced maximal blood concentrations of 10.8 +/- 5.6 micrograms/ml (mean +/- S.D., n = 10) at 90 to 100 min.",Evidence of significant absorption of sodium salicylate from urinary bladder of rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072307/),[μg] / [ml],10.8,204186,DB00936,Salicylic acid
,2072307,bioavailability,"The bioavailability of the intravesical dose, calculated from the blood data and the clearance of the i.v. doses, was between 4 and 23% and averaged about 13%.",Evidence of significant absorption of sodium salicylate from urinary bladder of rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072307/),%,4 and 23,204187,DB00936,Salicylic acid
,2072307,bioavailability,"The bioavailability of the intravesical dose, calculated from the blood data and the clearance of the i.v. doses, was between 4 and 23% and averaged about 13%.",Evidence of significant absorption of sodium salicylate from urinary bladder of rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2072307/),%,13,204188,DB00936,Salicylic acid
,23692061,AUC0-24,"On Day 7, mean per cent time intragastric pH >4 was 50.6% for PA32540 and 57.6% for EC-omeprazole 40 mg (P = 0.004) and geometric least squares mean AUC0-24 for omeprazole was 1446 h*ng/mL for PA32540 and 2558 h*ng/mL for EC-omeprazole 40 mg.","Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),[h·ng] / [ml],1446,207416,DB00936,Salicylic acid
,23692061,AUC0-24,"On Day 7, mean per cent time intragastric pH >4 was 50.6% for PA32540 and 57.6% for EC-omeprazole 40 mg (P = 0.004) and geometric least squares mean AUC0-24 for omeprazole was 1446 h*ng/mL for PA32540 and 2558 h*ng/mL for EC-omeprazole 40 mg.","Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),[h·ng] / [ml],2558,207417,DB00936,Salicylic acid
,23692061,Tmax,Day 7 median Tmax of omeprazole was 0.5 h for PA32540 and 1.25 h for EC-omeprazole 40 mg.,"Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),h,0.5,207418,DB00936,Salicylic acid
,23692061,Tmax,Day 7 median Tmax of omeprazole was 0.5 h for PA32540 and 1.25 h for EC-omeprazole 40 mg.,"Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23692061/),h,1.25,207419,DB00936,Salicylic acid
,9120826,serum binding,"[3H]MPA serum binding (between 81 and 89 %) was similar and concentration independent in the young and elderly subjects and the erythrocyte partitioning coefficient was about 1, indicating the absence of a significant accumulation of MPA in red blood cells.",Effect of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120826/),%,81 and 89,212126,DB00936,Salicylic acid
,9120826,partitioning coefficient,"[3H]MPA serum binding (between 81 and 89 %) was similar and concentration independent in the young and elderly subjects and the erythrocyte partitioning coefficient was about 1, indicating the absence of a significant accumulation of MPA in red blood cells.",Effect of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120826/),,1,212127,DB00936,Salicylic acid
,7834163,terminal plasma t1/2,"Under acidic urine conditions, salicylic acid (SA) had a terminal plasma t1/2 value of 3.29 +/- 0.52 hours while under alkaline urine conditions this t1/2 was significantly reduced to 2.50 +/- 0.41 hours (p = 0.0156).","Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),h,3.29,213740,DB00936,Salicylic acid
,7834163,t1/2,"Under acidic urine conditions, salicylic acid (SA) had a terminal plasma t1/2 value of 3.29 +/- 0.52 hours while under alkaline urine conditions this t1/2 was significantly reduced to 2.50 +/- 0.41 hours (p = 0.0156).","Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),h,2.50,213741,DB00936,Salicylic acid
,7834163,total oral body clearance,The total oral body clearance of salicylic acid under acidic conditions (1.38 +/- 0.43 l/h) is significantly lower than under alkaline urine conditions (2.27 +/- 0.83 l/h; p = 0.0410).,"Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),[l] / [h],1.38,213742,DB00936,Salicylic acid
,7834163,total oral body clearance,The total oral body clearance of salicylic acid under acidic conditions (1.38 +/- 0.43 l/h) is significantly lower than under alkaline urine conditions (2.27 +/- 0.83 l/h; p = 0.0410).,"Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),[l] / [h],2.27,213743,DB00936,Salicylic acid
,7834163,protein binding,The protein binding of SA was 93.8 +/- 1.0% and that of SU was 89.7 +/- 2.2% in vivo and in vitro.,"Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),%,93.8,213744,DB00936,Salicylic acid
,7834163,protein binding,The protein binding of SA was 93.8 +/- 1.0% and that of SU was 89.7 +/- 2.2% in vivo and in vitro.,"Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),%,89.7,213745,DB00936,Salicylic acid
,7834163,protein binding,"SUPG had a protein binding of 84.8 +/- 1.8%, while SAPG showed no protein binding at all.","Effect of urinary pH on the pharmacokinetics of salicylic acid, with its glycine and glucuronide conjugates in human. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834163/),%,84.8,213746,DB00936,Salicylic acid
,8925104,flow-rate,"The mobile phase was H2O-CH3CN-CH3COOH (100:3:1, pH 4.0) with a flow-rate of 1.5 ml/min.",Determination of p-aminobenzoic acid and its metabolites in rabbit plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925104/),[ml] / [min],1.5,217888,DB00936,Salicylic acid
,8925104,half-life,"After intravenous (i.v.) administration of PABA (20 mg/kg) to rabbits (n = 7), PABA followed a one-compartment open model elimination with a half-life of 10.90 +/- 1.03 min.",Determination of p-aminobenzoic acid and its metabolites in rabbit plasma by high-performance liquid chromatography with fluorescence detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925104/),min,10.90,217889,DB00936,Salicylic acid
,8925104,half lives,"The mean half lives for PAABA, PAHA and PAAHA were 24.61 +/- 6.42, 12.81 +/- 6.04 and 11.27 +/- 2.77 min, respectively.",Determination of p-aminobenzoic acid and its metabolites in rabbit plasma by high-performance liquid chromatography with fluorescence detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925104/),min,24.61,217890,DB00936,Salicylic acid
,8925104,half lives,"The mean half lives for PAABA, PAHA and PAAHA were 24.61 +/- 6.42, 12.81 +/- 6.04 and 11.27 +/- 2.77 min, respectively.",Determination of p-aminobenzoic acid and its metabolites in rabbit plasma by high-performance liquid chromatography with fluorescence detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925104/),min,12.81,217891,DB00936,Salicylic acid
,8925104,half lives,"The mean half lives for PAABA, PAHA and PAAHA were 24.61 +/- 6.42, 12.81 +/- 6.04 and 11.27 +/- 2.77 min, respectively.",Determination of p-aminobenzoic acid and its metabolites in rabbit plasma by high-performance liquid chromatography with fluorescence detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8925104/),min,11.27,217892,DB00936,Salicylic acid
,3190995,Steady-state concentrations,"3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment.",The effect of concurrent aspirin upon plasma concentrations of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190995/),,10.4,219117,DB00936,Salicylic acid
,3190995,Steady-state concentrations,"3. Steady-state concentrations of tenoxicam decreased significantly from 10.4 +/- 1.5 to 4.5 +/- 1.6 micrograms ml-1 in the presence of chronic, high-dose aspirin treatment.",The effect of concurrent aspirin upon plasma concentrations of tenoxicam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3190995/),,4.5,219118,DB00936,Salicylic acid
,19620655,apparent volume of distribution,"Mean intravenous salicylate apparent volume of distribution was 0.2 +/- 0.005 L/kg, total body clearance was 4.3 +/- 0.2 mL/min.kg, and elimination half-life was 36.9 +/- 1.2 min.",Analgesic efficacy of sodium salicylate in an amphotericin B-induced bovine synovitis-arthritis model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620655/),[l] / [kg],0.2,220864,DB00936,Salicylic acid
,19620655,total body clearance,"Mean intravenous salicylate apparent volume of distribution was 0.2 +/- 0.005 L/kg, total body clearance was 4.3 +/- 0.2 mL/min.kg, and elimination half-life was 36.9 +/- 1.2 min.",Analgesic efficacy of sodium salicylate in an amphotericin B-induced bovine synovitis-arthritis model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620655/),[ml] / [kg·min],4.3,220865,DB00936,Salicylic acid
,19620655,elimination half-life,"Mean intravenous salicylate apparent volume of distribution was 0.2 +/- 0.005 L/kg, total body clearance was 4.3 +/- 0.2 mL/min.kg, and elimination half-life was 36.9 +/- 1.2 min.",Analgesic efficacy of sodium salicylate in an amphotericin B-induced bovine synovitis-arthritis model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19620655/),min,36.9,220866,DB00936,Salicylic acid
,6144210,peak,"reached a peak (10.9 and 19.8 micrograms/ml in Subjects 1 and 2, respectively) and initially declined with a half-life of about two-three hours.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),[μg] / [ml],10.9,222732,DB00936,Salicylic acid
,6144210,peak,"reached a peak (10.9 and 19.8 micrograms/ml in Subjects 1 and 2, respectively) and initially declined with a half-life of about two-three hours.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),[μg] / [ml],19.8,222733,DB00936,Salicylic acid
,6144210,half-life,"reached a peak (10.9 and 19.8 micrograms/ml in Subjects 1 and 2, respectively) and initially declined with a half-life of about two-three hours.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),h,two-,222734,DB00936,Salicylic acid
,6144210,peak,"reached a peak (4.3, 10.0 micrograms/ml, respectively) and declined with a half-life of about one hour.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),[μg] / [ml],4.3,222735,DB00936,Salicylic acid
,6144210,peak,"reached a peak (4.3, 10.0 micrograms/ml, respectively) and declined with a half-life of about one hour.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),[μg] / [ml],10.0,222736,DB00936,Salicylic acid
,6144210,half-life,"reached a peak (4.3, 10.0 micrograms/ml, respectively) and declined with a half-life of about one hour.","The metabolism of the anti-inflammatory drug eterylate in rat, dog and man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144210/),h,one,222737,DB00936,Salicylic acid
,3888490,absorption half-life,Aspirin absorption follows first-order kinetics with an absorption half-life ranging from 5 to 16 minutes.,Clinical pharmacokinetics of the salicylates. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3888490/),min,5 to 16,227085,DB00936,Salicylic acid
,3888490,serum half-life,The serum half-life of aspirin is approximately 20 minutes.,Clinical pharmacokinetics of the salicylates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3888490/),min,20,227086,DB00936,Salicylic acid
,10497140,First order degradation half-lives,"First order degradation half-lives of 26 and 0. 5 h were observed on incubation in buffer of pH 7.4 for the 1-O-acylglucuronides of telmisartan and diclofenac, respectively.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),h,26,228719,DB00936,Salicylic acid
,10497140,First order degradation half-lives,"First order degradation half-lives of 26 and 0. 5 h were observed on incubation in buffer of pH 7.4 for the 1-O-acylglucuronides of telmisartan and diclofenac, respectively.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),h,0. 5,228720,DB00936,Salicylic acid
,10497140,clearance,"After i.v. dosing to rats, telmisartan 1-O-acylglucuronide was rapidly cleared from plasma with a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the parent compound.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),[ml] / [kg·min],180,228721,DB00936,Salicylic acid
,10497140,clearance,"After i.v. dosing to rats, telmisartan 1-O-acylglucuronide was rapidly cleared from plasma with a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the parent compound.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),[ml] / [kg·min],15.6,228722,DB00936,Salicylic acid
,14620867,elimination rate constant,"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),1/[h],1.32,228959,DB00936,Salicylic acid
,14620867,elimination half-life,"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),h,0.53,228960,DB00936,Salicylic acid
,14620867,area under the plasma concentration-versus-time curve (AUC),"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[min·μg] / [ml],2555,228961,DB00936,Salicylic acid
,14620867,plasma clearance,"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[ml] / [h·kg],472,228962,DB00936,Salicylic acid
,14620867,volume of distribution at steady state,"After IV administration, the mean elimination rate constant of ASA (+/- the standard error of the mean) was 1.32 +/- 0.09 h(-1), the mean elimination half-life was 0.53 +/- 0.04 h, the area under the plasma concentration-versus-time curve (AUC) was 2555 +/- 98 microg x min/mL, the plasma clearance was 472 +/- 18.9 mL/h/kg, and the volume of distribution at steady state was 0.22 +/- 0.01 L/kg.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[l] / [kg],0.22,228963,DB00936,Salicylic acid
,14620867,AUC,"After rectal administration, the AUC for ASA was 439.4 +/- 94.55 microg x min/mL and the bioavailability was 0.17 +/- 0.037.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[min·μg] / [ml],439.4,228964,DB00936,Salicylic acid
,14620867,bioavailability,"After rectal administration, the AUC for ASA was 439.4 +/- 94.55 microg x min/mL and the bioavailability was 0.17 +/- 0.037.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),,0.17,228965,DB00936,Salicylic acid
,14620867,AUC,"After IG administration, the AUC for ASA was 146.70 +/- 24.90 microg x min/mL and the bioavailability was 0.059 +/- 0.013.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),[min·μg] / [ml],146.70,228966,DB00936,Salicylic acid
,14620867,bioavailability,"After IG administration, the AUC for ASA was 146.70 +/- 24.90 microg x min/mL and the bioavailability was 0.059 +/- 0.013.","Pharmacokinetics and plasma concentrations of acetylsalicylic acid after intravenous, rectal, and intragastric administration to horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620867/),,0.059,228967,DB00936,Salicylic acid
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,30,229859,DB00936,Salicylic acid
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,45,229860,DB00936,Salicylic acid
,22326030,T(max),"ST0702 is metabolised in vivo to aspirin, niacin and salicylic acid with T(max) values of 30, 45 and 95 min respectively using a non-compartmental model.",In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326030/),min,95,229861,DB00936,Salicylic acid
,8735416,elimination rate constant (k(el)),For control animals the elimination rate constant (k(el)) and total body clearance (Cl) were 1.35 +/- 0.43 h-1 and 20.2 +/- 6.1 ml/h.kg respectively (mean +/- SD).,The pharmacokinetics of salicylate in dairy cattle are not altered by simultaneous intravenous ceftiofur sodium and DL-lysine-acetyl salicylate (aspirin). ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735416/),1/[h],1.35,230311,DB00936,Salicylic acid
,8735416,total body clearance (Cl),For control animals the elimination rate constant (k(el)) and total body clearance (Cl) were 1.35 +/- 0.43 h-1 and 20.2 +/- 6.1 ml/h.kg respectively (mean +/- SD).,The pharmacokinetics of salicylate in dairy cattle are not altered by simultaneous intravenous ceftiofur sodium and DL-lysine-acetyl salicylate (aspirin). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735416/),[ml] / [h·kg],20.2,230312,DB00936,Salicylic acid
,10366903,RSD%,RSD% of 0.5% have become standard for quality control assays.,Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),%,0.5,236201,DB00936,Salicylic acid
,10366903,total analysis time,"A number of pharmaceuticals (e.g. acetaminophen, salicylic acid, sulfamethoxazole, theophylline, tolbutamide, and trimethoprim) have been determined in human plasma on underivatized fused silica capillaries by MEKC without sample pretreatment, the total analysis time being only 10 min.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),min,10,236202,DB00936,Salicylic acid
,10366903,detection limit,"The separation system is tested in a concentration range between 10 ng/mL and 100 micrograms/mL, the detection limit being about 5 ng/mL.",Pharmacokinetic investigations with direct injection of plasma samples: possible savings using capillary electrophoresis (CE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10366903/),[ng] / [ml],5,236203,DB00936,Salicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,178.9,241179,DB00936,Salicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,136.8,241180,DB00936,Salicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,137.0,241181,DB00936,Salicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,93.0,241182,DB00936,Salicylic acid
,19358313,m/z,"The multiple reaction monitoring mode was used with ion transitions of m/z 178.9 --> 136.8, 137.0 --> 93.0 and 167.0 --> 123.0 for ASA, SA and IS, respectively.",Rapid and sensitive determination of acetylsalicylic acid and salicylic acid in plasma using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19358313/),,167.0,241183,DB00936,Salicylic acid
,2719746,half-life,After intravenous administration fosfosal plasma levels decreased rapidly showing a half-life of 2.7 min in rats and 6.7 min in dogs.,Pharmacokinetics of fosfosal in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719746/),min,2.7,241856,DB00936,Salicylic acid
,2719746,half-life,After intravenous administration fosfosal plasma levels decreased rapidly showing a half-life of 2.7 min in rats and 6.7 min in dogs.,Pharmacokinetics of fosfosal in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719746/),min,6.7,241857,DB00936,Salicylic acid
,2719746,half-life,"The half-life of salicylic acid was 13.8 and 7.1 h for rats and dogs, respectively.",Pharmacokinetics of fosfosal in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719746/),h,13.8,241858,DB00936,Salicylic acid
,2719746,half-life,"The half-life of salicylic acid was 13.8 and 7.1 h for rats and dogs, respectively.",Pharmacokinetics of fosfosal in rats and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2719746/),h,7.1,241859,DB00936,Salicylic acid
,3793293,t1/2 beta,"The t1/2 beta for imidazole (oral administration) was determined for a single dose at 2.98 +/- 1.13 h, for a multiple dose (last dose) at 1.86 +/- 0.78 h; for salicylic acid the t1/2 beta for a single dose was determined at 6.46 +/- 3.79 h and for a multiple dose (last dose) at 6.40 +/- 3.36 h.","Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),h,2.98,242553,DB00936,Salicylic acid
,3793293,t1/2 beta,"The t1/2 beta for imidazole (oral administration) was determined for a single dose at 2.98 +/- 1.13 h, for a multiple dose (last dose) at 1.86 +/- 0.78 h; for salicylic acid the t1/2 beta for a single dose was determined at 6.46 +/- 3.79 h and for a multiple dose (last dose) at 6.40 +/- 3.36 h.","Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),h,1.86,242554,DB00936,Salicylic acid
,3793293,t1/2 beta,"The t1/2 beta for imidazole (oral administration) was determined for a single dose at 2.98 +/- 1.13 h, for a multiple dose (last dose) at 1.86 +/- 0.78 h; for salicylic acid the t1/2 beta for a single dose was determined at 6.46 +/- 3.79 h and for a multiple dose (last dose) at 6.40 +/- 3.36 h.","Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),h,6.46,242555,DB00936,Salicylic acid
,3793293,t1/2 beta,"The t1/2 beta for imidazole (oral administration) was determined for a single dose at 2.98 +/- 1.13 h, for a multiple dose (last dose) at 1.86 +/- 0.78 h; for salicylic acid the t1/2 beta for a single dose was determined at 6.46 +/- 3.79 h and for a multiple dose (last dose) at 6.40 +/- 3.36 h.","Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),h,6.40,242556,DB00936,Salicylic acid
,3793293,protein-binding,The protein-binding of imidazole was in the range of 5-15% and of salicylic acid of about 80-85%.,"Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),%,5-15,242557,DB00936,Salicylic acid
,3793293,protein-binding,The protein-binding of imidazole was in the range of 5-15% and of salicylic acid of about 80-85%.,"Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),%,80-85,242558,DB00936,Salicylic acid
,3793293,relative bioavailability,The relative bioavailability was calculated for imidazole (single dose) at 138% and for multiple dosing (last dose) at 113%; for salicylic acid the values for single dose were 148% and for multiple dosing (last dose) 128%.,"Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),%,138,242559,DB00936,Salicylic acid
,3793293,relative bioavailability,The relative bioavailability was calculated for imidazole (single dose) at 138% and for multiple dosing (last dose) at 113%; for salicylic acid the values for single dose were 148% and for multiple dosing (last dose) 128%.,"Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),%,113,242560,DB00936,Salicylic acid
,3793293,relative bioavailability,The relative bioavailability was calculated for imidazole (single dose) at 138% and for multiple dosing (last dose) at 113%; for salicylic acid the values for single dose were 148% and for multiple dosing (last dose) 128%.,"Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),%,148,242561,DB00936,Salicylic acid
,3793293,relative bioavailability,The relative bioavailability was calculated for imidazole (single dose) at 138% and for multiple dosing (last dose) at 113%; for salicylic acid the values for single dose were 148% and for multiple dosing (last dose) 128%.,"Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3793293/),%,128,242562,DB00936,Salicylic acid
,1184427,half-time of absorption,"Despite slow absorption (half-time of absorption, 2.91 hours) of orally administered aspirin and rapid elimination (biologic half-life, 32 minutes) of salicylates, oral dosage of 100 mg/kg every 12 hours maintained serum salicylate concentration greater than 30 mug/ml, which was considered to be therapeutically effective.",Pharmacokinetics and dosage of aspirin in cattle. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184427/),h,2.91,243264,DB00936,Salicylic acid
,1184427,biologic half-life,"Despite slow absorption (half-time of absorption, 2.91 hours) of orally administered aspirin and rapid elimination (biologic half-life, 32 minutes) of salicylates, oral dosage of 100 mg/kg every 12 hours maintained serum salicylate concentration greater than 30 mug/ml, which was considered to be therapeutically effective.",Pharmacokinetics and dosage of aspirin in cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1184427/),min,32,243265,DB00936,Salicylic acid
,4026924,absolute bioavailability,The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application.,[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,68,246405,DB00936,Salicylic acid
,4026924,absolute bioavailability,The mean absolute bioavailability of acetylsalicylic acid was 68% after oral application and 60% after rectal application.,[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,60,246406,DB00936,Salicylic acid
,4026924,bioavailability,"The corresponding bioavailability data of codeine were 59% and 63%, respectively.",[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,59,246407,DB00936,Salicylic acid
,4026924,bioavailability,"The corresponding bioavailability data of codeine were 59% and 63%, respectively.",[The bioavailability of combination preparations of acetylsalicylic acid and codeine phosphate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026924/),%,63,246408,DB00936,Salicylic acid
,2038097,Vss,"Following i.v. administration, SA was distributed with a Vss of 0.249 +/- 0.082 l/kg and cleared at a rate of 0.0432 +/- 0.006 l/h/kg.",Pharmacokinetics and elimination of salicylic acid in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038097/),[l] / [kg],0.249,247160,DB00936,Salicylic acid
,2038097,rate,"Following i.v. administration, SA was distributed with a Vss of 0.249 +/- 0.082 l/kg and cleared at a rate of 0.0432 +/- 0.006 l/h/kg.",Pharmacokinetics and elimination of salicylic acid in rabbits. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038097/),[l] / [h·kg],0.0432,247161,DB00936,Salicylic acid
,2038097,biological half-life,"The biological half-life, calculated from the terminal disposition-rate constant, was 4.3 h (i.v.) or 9.7 h (p.o.).",Pharmacokinetics and elimination of salicylic acid in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038097/),h,4.3,247162,DB00936,Salicylic acid
,2038097,biological half-life,"The biological half-life, calculated from the terminal disposition-rate constant, was 4.3 h (i.v.) or 9.7 h (p.o.).",Pharmacokinetics and elimination of salicylic acid in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038097/),h,9.7,247163,DB00936,Salicylic acid
,27978468,flow rate,The separation of two components was achieved by using an ACQUITY UPLC ®BEH C18 Column (1.7μm 2.1×100mm) by gradient elution using water (containing 0.2% formic acid) and acetonitrile (containing 0.2% formic acid) as the mobile phase at a flow rate of 0.2mL/min.,Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27978468/),[ml] / [min],0.2,250704,DB00936,Salicylic acid
,3582638,half-life,"The half-life in elderly patients was 6.19 hrs, in old patients 12.2 hrs and in young patients 4.47 hrs.",[Age-related characteristics of the pharmacokinetics of acetylsalicylic acid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582638/),h,6.19,252576,DB00936,Salicylic acid
,3582638,half-life,"The half-life in elderly patients was 6.19 hrs, in old patients 12.2 hrs and in young patients 4.47 hrs.",[Age-related characteristics of the pharmacokinetics of acetylsalicylic acid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582638/),h,12.2,252577,DB00936,Salicylic acid
,3582638,half-life,"The half-life in elderly patients was 6.19 hrs, in old patients 12.2 hrs and in young patients 4.47 hrs.",[Age-related characteristics of the pharmacokinetics of acetylsalicylic acid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582638/),h,4.47,252578,DB00936,Salicylic acid
,1789461,recovery,The average recovery from serum was found to be 60% with a relative standard deviation of 5.8%.,Voltammetric behaviour of salicylic acid at a glassy carbon electrode and its determination in serum using liquid chromatography with amperometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1789461/),%,60,254767,DB00936,Salicylic acid
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],3.71,255499,DB00936,Salicylic acid
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],15.8,255500,DB00936,Salicylic acid
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],2.42,255501,DB00936,Salicylic acid
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],3.89,255502,DB00936,Salicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],2.86,255503,DB00936,Salicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],60.5,255504,DB00936,Salicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],7.68,255505,DB00936,Salicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],2.96,255506,DB00936,Salicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],59.1,255507,DB00936,Salicylic acid
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],7.77,255508,DB00936,Salicylic acid
,2292770,rate constant,"Pharmacokinetic analysis for the plasma or medium concentration of SA after perfusion showed that SA was absorbed at the rate constant of 0.071 h-1, and that approximately 70% of SA absorbed from oral mucosa was transferred to the circulating blood.",In situ perfusion system for oral mucosal absorption in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292770/),1/[h],0.071,256829,DB00936,Salicylic acid
,7391154,recovery of,"The recovery of the extraction was found to be 88% and 77% for indomethacin and salicylic acid, respectively.",Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),%,88,257472,DB00936,Salicylic acid
,7391154,recovery of,"The recovery of the extraction was found to be 88% and 77% for indomethacin and salicylic acid, respectively.",Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),%,77,257473,DB00936,Salicylic acid
,7391154,detection limits,The detection limits for indomethacin and salicylic acid were 2 ng.,Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391154/),ng,2,257474,DB00936,Salicylic acid
,29329092,flow rate,The separation of six components was achieved by using an ACQUITY UPLC ®BEH C18 column (1.7μm 2.1×100mm) by gradient elution using water (containing 0.2% formic acid) and acetonitrile (containing 0.2% formic acid) as the mobile phase at a flow rate of 0.2mL/min.,Effect of aspirin on the pharmacokinetics and absorption of panax notoginseng saponins. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29329092/),[ml] / [min],0.2,264612,DB00936,Salicylic acid
,3403104,maximum concentration,"Salicylic acid showed a maximum concentration 59.2 +/- 5 min and 75.4 +/- 7.6 min after the administration of the tablet and suppository respectively; and imidazole after 86.3 +/- 10.8 min and 75.2 +/- 5.4 min, respectively.",Comparative absorption kinetics of imidazole and salicylic acid in volunteers after administration of ITF 182 tablets and suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403104/),min,59.2,265206,DB00936,Salicylic acid
,3403104,maximum concentration,"Salicylic acid showed a maximum concentration 59.2 +/- 5 min and 75.4 +/- 7.6 min after the administration of the tablet and suppository respectively; and imidazole after 86.3 +/- 10.8 min and 75.2 +/- 5.4 min, respectively.",Comparative absorption kinetics of imidazole and salicylic acid in volunteers after administration of ITF 182 tablets and suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403104/),min,75.4,265207,DB00936,Salicylic acid
,3403104,maximum concentration,"Salicylic acid showed a maximum concentration 59.2 +/- 5 min and 75.4 +/- 7.6 min after the administration of the tablet and suppository respectively; and imidazole after 86.3 +/- 10.8 min and 75.2 +/- 5.4 min, respectively.",Comparative absorption kinetics of imidazole and salicylic acid in volunteers after administration of ITF 182 tablets and suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403104/),,86,265208,DB00936,Salicylic acid
,3403104,maximum concentration,"Salicylic acid showed a maximum concentration 59.2 +/- 5 min and 75.4 +/- 7.6 min after the administration of the tablet and suppository respectively; and imidazole after 86.3 +/- 10.8 min and 75.2 +/- 5.4 min, respectively.",Comparative absorption kinetics of imidazole and salicylic acid in volunteers after administration of ITF 182 tablets and suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3403104/),,75.2,265209,DB00936,Salicylic acid
,23526241,AUC0-t,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],52.69,265364,DB00936,Salicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 378.62,265365,DB00936,Salicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[1] / [h],0.75,265366,DB00936,Salicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 314.17,265367,DB00936,Salicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[h·ng] / [ml],1 314.50,265368,DB00936,Salicylic acid
,23526241,Cmax/AUC0-∞,"The mean pharmacokinetic parameters (AUC0-t, AUC0-∞, Cmax, Cmax /AUC0-t and Cmax/AUC0-∞) for atorvastatin test and reference formulations were (52.69 ng.h/mL, 55.64 ng.h/mL, 9.45 ng/mL, 0.18 1/h and 0.17 1/h) and (52.20 ng.h/mL, 55.38 ng.h/mL, 10.25 ng/mL, 0.20 1/h and 0.19 1/h) respectively; and for aspirin were (1 378.62 ng.h/mL, 1 383.90 ng.h/mL, 1 022.18 ng/mL, 0.75 1/h and 0.75 1/h) and (1 314.17 ng.h/mL, 1 314.50 ng.h/mL, 985.90 ng/mL, 0.75 1/h and 0.75 1/h) respectively.","Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23526241/),[ng] / [ml],985.90,265369,DB00936,Salicylic acid
,9084459,time to reach peak concentration,"With the exception of nicotine time to reach peak concentration, which was longer in patients (median of 60 minutes compared with 45 minutes; p < 0.005), other comparisons between normal subjects and patients showed no statistically significant difference, although there was considerable inter-subject variation.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),min,60,270129,DB00936,Salicylic acid
,9084459,time to reach peak concentration,"With the exception of nicotine time to reach peak concentration, which was longer in patients (median of 60 minutes compared with 45 minutes; p < 0.005), other comparisons between normal subjects and patients showed no statistically significant difference, although there was considerable inter-subject variation.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),min,45,270130,DB00936,Salicylic acid
,9084459,Maximum concentration,"Maximum concentration of nicotine, 8.1 +/- 3.5 ng/ml, in the 16 subjects occurred after a median of 60 minutes (range, 30 to 180 minutes); maximum cotinine concentrations of 60.4 +/- 11.5 ng/ml occurred after 4 hours.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),[ng] / [ml],8.1,270131,DB00936,Salicylic acid
,9084459,maximum cotinine concentrations,"Maximum concentration of nicotine, 8.1 +/- 3.5 ng/ml, in the 16 subjects occurred after a median of 60 minutes (range, 30 to 180 minutes); maximum cotinine concentrations of 60.4 +/- 11.5 ng/ml occurred after 4 hours.",Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084459/),[ng] / [ml],60.4,270132,DB00936,Salicylic acid
,7752618,maximal serum SA concentration,"Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively.",Disposition kinetics of aspirin in female New Zealand white rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752618/),[μg] / [ml],7.54,270861,DB00936,Salicylic acid
,7752618,maximal serum SA concentration,"Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively.",Disposition kinetics of aspirin in female New Zealand white rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752618/),[μg] / [ml],22.65,270862,DB00936,Salicylic acid
,7752618,maximal serum SA concentration,"Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively.",Disposition kinetics of aspirin in female New Zealand white rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752618/),[μg] / [ml],43.2,270863,DB00936,Salicylic acid
,7752618,maximal serum SA concentration,"Mean maximal serum SA concentration was 7.54, 22.65, 43.2, and 70 micrograms/ml for the 2.5, 10, 20, and 50 mg/kg doses respectively.",Disposition kinetics of aspirin in female New Zealand white rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752618/),[μg] / [ml],70,270864,DB00936,Salicylic acid
